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Abstract 
ABSTRACT 
Anniina Keskitalo (née Rintala) 
Gut microbes in the prevention and onset of metabolic disorders 
University of Turku, Faculty of Medicine, Institute of Biomedicine, Medical 
Microbiology and Immunology, Turku Doctoral Programme of Molecular 
Medicine (TuDMM) 
Annales Universitatis Turkuensis, Medica - Odontologica, Turku, 2019 
Gut microbes are suggested to play an essential role in maintaining human 
health, and unfavorable alterations in gut microbiota have been associated with 
several human diseases and disorders. Despite the significant advancements in 
analysis tools, several sources of uncertainty still exist in the gut microbiota 
composition analyses, limiting the reproducibility and comparability of the 
results from distinct gut microbiota studies. 
The first main aim of this study was to set up a functional high-throughput 
pipeline for 16S rRNA gene sequencing -based gut microbiota composition 
analysis. This was achieved by evaluating the effects of fecal sample processing, 
i.e. two sample storage conditions and five DNA extraction kits, along with two 
different 16S rRNA gene sequencing protocols. The second main aim of this 
study was to explore the role of gut microbiota in the onset of obesity-related 
metabolic disorders such as non-alcoholic fatty liver disease. This was done by 
studying the effects of intragastric administration of two distinct gut microbes, 
Faecalibacterium prausnitzii and Enterobacter cloacae, on host health and 
metabolism of high fat diet -fed C57BL/6N mice. 
The results of this study showed that the 16S rRNA gene sequencing protocol 
had a significant effect on the analysis results. Meanwhile, the effect of sample 
pre-processing was more modest, yet still potentially important. These results 
indicate that careful design and adequate method optimization are required in 
order to produce reliable 16S rRNA gene sequencing results. Moreover, the 
results of this study revealed that the intragastric F. prausnitzii administration 
appeared to protect the C57BL/6N mice from liver steatosis, whereas the 
intragastric administration of E. cloacae seemed to induce liver damage. Further 
studies are needed in order to clarify the underlying mechanisms and to fully 
elucidate the possible therapeutic potential of F. prausnitzii. 
Keywords: gut microbiota, 16S rRNA gene sequencing, metabolic disorders, 
non-alcoholic fatty liver disease 
 
Tiivistelmä 
TIIVISTELMÄ 
Anniina Keskitalo (née Rintala) 
Suolistomikrobiston rooli lihavuuteen liittyvien aineenvaihduntahäiriöiden 
synnyssä ja ehkäisyssä 
Turun yliopisto, Lääketieteellinen tiedekunta, Biolääketieteen laitos, 
Lääketieteellinen mikrobiologia ja immunologia, Turun molekyylilääketieteen 
tohtoriohjelma (TuDMM) 
Annales Universitatis Turkuensis, Medica - Odontologica, Turku, 2019 
Suolistobakteereilla uskotaan olevan merkittävä vaikutus ihmisen terveydelle, ja 
suolistomikrobiston epätasapaino on yhdistetty moniin eri sairauksiin ja 
oireyhtymiin. Mikrobistotutkimuksessa käytettävät analyysimenetelmät ovat 
viimeisen vuosikymmenen aikana kehittyneet merkittävästi, mutta 
analyysitulokset ovat yhä vahvasti menetelmäriippuvaisia, mikä heikentää 
tutkimusten toistettavuutta sekä tulosten luotettavuutta ja vertailukelpoisuutta. 
Tämän tutkimuksen ensimmäisenä päätavoitteena oli pystyttää toimivat 
menetelmät 16S rRNA -geenisekvensointiin perustuvalle mikrobistoanalytiikalle. 
Tutkimuksessa vertailtiin viittä eri DNA-eristysmenetelmää sekä kahta eri 
sekvensointiprotokollaa, ja selvitettiin ulostenäytteiden pakastuksen vaikutusta 
mikrobistoanalyysin tuloksiin. Tutkimuksen toisena päätavoitteena oli kartoittaa 
hiirimallin avulla suolistomikrobiston roolia ei-alkoholiperäisen rasvamaksan 
synnyssä. Tutkimuksessa selvitettiin, miten suun kautta tapahtuva 
Faecalibacterium prausnitzii- tai Enterobacter cloacae -annostelu vaikutti 
korkearasvaista ravintoa syövien C57BL/6N-hiirten terveyteen ja 
aineenvaihduntaan. 
Tutkimuksen tulokset osoittivat, että 16S rRNA -geenisekvensointimenetelmällä 
oli merkittävä vaikutus mikrobistoanalyysista saataviin tuloksiin. Näytteiden 
esikäsittelyn vaikutus oli huomattavasti vähäisempi, mutta kuitenkin tulosten 
vertailukelpoisuuden kannalta mahdollisesti merkityksellinen. Tulokset 
osoittavat, että huolellinen suunnittelu ja asianmukainen menetelmäoptimointi 
ovat välttämättömiä luotettavien 16S rRNA -geenisekvensointituloksen 
tuottamiseksi. Lisäksi tämän tutkimuksen tulokset osoittivat, että F. prausnitzii -
annostelu vaikutti positiivisesti hiirten aineenvaihduntaan ja vähensi hiirten 
maksan rasvoittumista, kun taas E. cloacae -annostelu aiheutti maksavaurioita. F. 
prausnitzii -suolistobakteerin mahdollista terveyttä edistävää potentiaalia ja 
taustalla olevia tekijöitä tulisi selvittää tarkemmissa jatkotutkimuksissa. 
Avainsanat: suolistomikrobisto, 16S rRNA geenisekvensointi, metabolinen 
oireyhtymä, ei-alkoholiperäinen rasvamaksa 
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1 INTRODUCTION 
Human gastrointestinal (GI) tract is densely colonized by microbial inhabitants, 
and the balance and welfare of these microbes appears to be crucial for human 
health (Sekirov et al., 2010, Wu et al., 2015, Lynch & Pedersen, 2016). During 
the past decade, significant methodological and technological advancements have 
provided completely new approaches to study the composition and functions of 
the gut bacteria (Klindworth et al., 2013, Lepage et al., 2013, Mandal et al., 
2015), and consequently, the amount of information concerning the intestinal 
microbiota composition, along with possible host-bacterial interactions, has 
increased enormously (Chow et al., 2010, Tremaroli & Bäckhed, 2012, McLean 
et al., 2015, Stenman et al., 2015, Gérard, 2016, Zhernakova et al., 2016, Jackson 
et al., 2018). 
Obesity has become a global health burden; the worldwide number of obese adult 
individuals is already reaching 2 billion, and the prevalence is constantly 
increasing (World Health Organization, 2017). As a consequence, the incidence 
of obesity-associated metabolic disorders has also increased. For example, non-
alcoholic fatty liver disease (NAFLD), the so-called hepatic manifestation of 
metabolic syndrome, has become the most common liver disorder in the Western 
world (Henao-Mejia et al., 2013). Even though obesity and the associated 
metabolic disorders are generally considered to result from unhealthy diet and 
lifestyle, constantly accumulating evidence indicates that gut microbiota may 
play an important role in the development of the obesity-related metabolic 
disorders such as insulin resistance (IR), Type 2 diabetes (T2D), and NAFLD 
(Shen et al., 2013, Cani & Delzenne, 2014, Alard et al., 2016, Xie et al., 2016). 
Faecalibacterium prausnitzii is a commensal gut bacterium that conceivably 
supports host health and serves as a potential indicator of a healthy human gut 
(reviewed in Ferreira-Halder et al., 2017). By contrast, family 
Enterobacteriaceae, and particularly Enterobacter cloacae strain B29, have been 
associated with obesity and hepatic damage (Fei & Zhao, 2013, Munukka et al., 
2016). The underlying mechanisms behind the reported associations remain 
largely unknown. This study aimed at illustrating the mechanisms underlying the 
proposed health-promoting or -compromising effects of these gut bacteria by 
examining the effects of intragastric administration of either F. prausnitzii 
(ATCC® 27766™) or E. cloacae subsp. cloacae (ATCC® 13047™) on host 
health and metabolism of high-fat diet (HFD) fed C57BL/6N mice. 
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2 REVIEW OF LITERATURE 
2.1 Gut Microbiota 
Human gut harbors one of the most complex microbial ecosystems on Earth, 
comprised of trillions of microbes (Whitman et al., 1998, Sekirov et al., 2010, 
Huttenhower et al., 2012, Sankar et al., 2015). Term ‘gut microbiota’ refers to all 
the GI tract microbes, including bacteria, archaea, eukaryotes, and viruses 
(Zoetendal et al., 2008, Rajilić-Stojanović & de Vos, 2014). Until recently, 
bacteria were thought to represent the most diverse and abundant microbial group 
residing in the human GI tract (Rajilić-Stojanović & de Vos, 2014). Recent 
studies have, however, reported that intestinal viruses, specifically 
bacteriophages, represent a remarkably diverse population that may actually 
clearly outnumber the bacterial inhabitants of the gut (Bakhshinejad & 
Ghiasvand, 2017, Cani, 2018). The overall diversity and clinical significance of 
the GI tract bacteriophages still remain largely unknown, but it has been stated 
that the phages may play an important role in human health and disease 
(Bakhshinejad & Ghiasvand, 2017, Cani, 2018). This literature review focuses on 
the bacterial population of the gut microbiota, which at present is the most 
comprehensively studied microbial group colonizing the human gut (Cani, 2018). 
The bacterial community inhabiting the human GI tract is dominated by 
anaerobic bacteria (Rajilić-Stojanović & de Vos, 2014). The proportion of 
bacterial cells increases dramatically from stomach to colon, and especially colon 
maintains an exceptionally diverse bacterial population (Sekirov et al., 2010, 
Sankar et al., 2015). In fact, colon microbiota has been suggested to be one of the 
most important microbial communities within the host, and the composition and 
functions of the ecosystem have thus been particularly intensively studied 
(Rajilić-Stojanović & de Vos, 2014, Sankar et al., 2015, Cani, 2018). The most 
predominant bacterial phyla residing in the human GI tract are Bacteroidetes and 
Firmicutes; these two phyla generally constitute more than 90 % of all gut 
bacteria in healthy adult individuals (Eckburg et al., 2005, Arumugam et al., 
2011). Bacteroidetes is comprised of Gram-negative bacteria, whereas 
Firmicutes is comprised mainly of Gram-positive bacteria. Other prevalent phyla 
include Actinobacteria and Proteobacteria, followed by sparser groups such as 
Fusobacteria and Verrucomicrobia (Table 1; Zoetendal et al., 2008, Arumugam 
et al., 2011, Rajilić-Stojanović & de Vos, 2014). 
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Table 1. The main bacterial groups present in the human GI tract microbiota (for a 
detailed review, see Rajilić-Stojanović & de Vos, 2014) 
Phylum General properties Examples of genera and species 
Firmicutes 
 
• Extremely diverse phylum including both 
commensal bacteria and opportunistic pathogens; 
class Clostridia includes species dominant in the 
lower GI tract, whereas class Bacilli includes 
species dominant in the upper parts of the GI tract.  
• Mainly Gram-positive bacilli/cocci 
• Several spore-forming species 
• Significant role in food metabolism, several 
important butyrate producers 
• Phylum includes several commercially applied 
probiotics and potential future probiotics, but also 
important pathogens such as C. difficile 
Clostridia: 
Clostridium: C. perfringens 
Eubacterium: E. rectale 
Faecalibacterium: F. prausnitzii 
Ruminococcus spp., Blautia spp., 
Dorea spp. 
Bacilli: 
Bacillus: Bacillus cereus 
Lactobacillus: L. acidophilus, L. casei 
Streptococcus spp., Enterococcus spp., 
Staphylococcus spp., Veillonella spp. 
Bacteroidetes • Substantially diverse phylum including both 
commensal bacteria and opportunistic pathogens 
• Gram-negative bacilli 
• Some species possess ability to degrade complex 
polysaccharides  
• Broad metabolic potential, health effects not fully 
elucidated 
Bacteroides: B. fragilis, B. dorei, 
B. thetaiotaomicron, B. vulgatus 
Prevotella: P. melaninogenica 
Actinobacteria • Gram-positive bacteria, typically difficult to lyse 
• High G+C content in DNA 
• Often underrepresented in 16S rRNA gene 
sequencing -based gut microbiota surveys 
• Several important carbohydrate fermenters 
• Certain Bifidobacterium strains are considered as 
health-beneficial and are commercially applied as 
probiotics 
Bifidobacterium: B. adolescentis,  
B. breve, B. longum 
Collinsella: C. aerofaciens 
Proteobacteria 
 
• Gram-negative bacilli, divided into several classes 
based on 16S rRNA sequence 
• Relatively low overall abundance in a healthy gut 
• Accurate genus level identification not feasible with 
current 16S rRNA gene sequencing -based gut 
microbiota composition analysis tools 
• Enterobacteriaceae, belonging to class γ-
Proteobacteria , possess both flagella and LPS, and 
are thus considered as pro-inflammatory 
• Phylum includes a wide variety of important GI 
tract pathogens, but certain species have also been 
commercially applied as probiotics 
β-Proteobacteria:  
Suttetella spp. 
γ-Proteobacteria: 
Enterobacter: E. cloacae 
Escherichia: E. coli 
Haemophilus spp., 
Pseudomonas spp. 
δ-Proteobacteria:  
Desulfovibrio spp. 
ε-Proteobacteria: 
Campylobacter spp., 
Helicobacter spp. 
Fusobacteria • Gram-negative, non-spore-forming bacilli 
• Generally considered as pro-inflammatory 
Fusobacterium: F. nucleatum 
Verrucomicrobia • Gram-negative, non-spore-forming 
• A. muciniphila is a mucin degrader that is suggested 
to be important for host health 
Akkermansia: A. muciniphila 
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Altogether, representatives from more than 10 different bacterial phyla have been 
detected from human GI tract samples, and it should be noted that most of these 
phyla are comprised of extremely large collections of bacterial species that 
possess divergent properties and functions (Rajilić-Stojanović & de Vos, 2014, 
Hugon et al., 2015, Marchesi et al., 2016). Furthermore, comprehensive coverage 
of the human gut microbiota composition and diversity is yet to be achieved; 
even though more than a thousand distinct human GI tract micro-organisms have 
already been isolated and identified, it has been predicted that part of the 
bacterial inhabitants may still remain completely uncharacterized (Lagier et al., 
2012, Rajilić-Stojanović & de Vos, 2014, Sankar et al., 2015, Browne et al., 
2016). 
The composition of gut microbiota is host specific and evolving throughout an 
individual’s life (Lozupone et al., 2012, Kundu et al., 2017). Until recently, 
human placenta and developing fetus have been regarded as sterile, while the 
initial microbe contact of the offspring has been assumed to occur during birth. 
Several recent studies have, however, challenged this sterility dogma by 
reporting findings of microbes, or at least traces of microbial DNA, in womb, 
placenta, umbilical cord blood, and amniotic fluid (Rautava et al., 2012, Zheng et 
al., 2015, Verstraelen et al., 2016). These findings suggest that, instead of 
maintaining a completely sterile environment for the developing offspring, the 
human placenta may act as a selective barrier allowing certain maternal microbes 
to colonize the fetus in utero (Funkhouser & Bordenstein, 2013, Kundu et al., 
2017). Nevertheless, as specimens with zero/low bacterial biomass are highly 
predisposed to external contamination during sample collection and analysis, it 
has been suggested that the results of these studies could be biased (Kundu et al., 
2017). Thus, no firm consensus on the issue has been reached to date. In either 
case, the major colonization of infant gut microbiota begins at birth (Milani et al., 
2017).  
Delivery mode and lactation play a significant role in early gut microbiota 
development (Grölund et al., 1999, Penders et al., 2006, Huurre et al., 2008, 
Dominguez-Bello et al., 2010), while introduction of solid foods is suggested to 
be the initial step for more rapid microbiota diversification and maturation 
(Milani et al., 2017, Kundu et al., 2017). Gut microbiota profile of a three-year-
old child already partially resembles the gut microbiota of an adult (Yatsunenko 
et al., 2012, Cheng et al., 2016), but the microbiota composition and diversity 
seem to undergo constant gradual development until early adulthood (Hollister et 
al., 2015, Odamaki et al., 2016). Accordingly, the maturation of human gut 
microbiota is suggested to proceed in parallel with the development of host 
intestine (Kundu et al., 2017); the bacterial diversity increases as the intestine 
elongates with age, finally reaching a total mucosal area of ~32 m2 on average 
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(Helander & Fändriks, 2014, Kundu et al., 2017). In adults, the GI tract 
microbiota is assumed to be a rather steady, yet dynamic, ecosystem (Costello et 
al., 2009, Chow et al., 2010, Lozupone et al., 2012). Based on recent large 
population-based studies, the most important underlying factors affecting the 
adulthood gut microbiota composition include environmental factors such as diet, 
lifestyle, and medication, along with host-related factors including age, gender, 
and body mass index (BMI) (Falony et al., 2016, Zhernakova et al., 2016, Haro 
et al., 2016). Role of genetic or ancestral background, on the other hand, is 
suggested to be minor (Jackson et al., 2018, Rothschild et al., 2018), although 
contradictory reports also exist (Goodrich et al., 2014, Lim et al., 2017). 
Most gut bacteria are harmless to the host, and humans along with several 
animals have evolved a symbiotic relationship with the gut microbes (Tremaroli 
& Bäckhed, 2012, Lepage et al., 2013). Gut bacteria, for example, participate in 
food digestion (chapter 2.1.1) and have an important role in protecting the host 
from invading pathogens (chapter 2.1.2). In fact, as the ecosystem constituted by 
the intestinal bacteria is both metabolically highly active and in constant 
interaction with the host, it has been stated that the gut microbiota should be 
referred as an “external organ” that is integrated in the host’s metabolism 
(Bäckhed et al., 2005, Lepage et al., 2013). 
2.1.1 Role of gut bacteria in food digestion and metabolism 
Gut microbes have an essential role in the food digestion of the host (Tremaroli 
& Bäckhed, 2012). Gut bacteria, for example, can biosynthesize vitamins from 
several precursors derived from ingested food, regulate bile acid metabolism, and 
utilize nutrients that would otherwise remain non-digestible for the host 
(Bäckhed et al., 2004, Tremaroli & Bäckhed, 2012, Yatsunenko et al., 2012). 
Accordingly, the intestinal bacteria are able to produce metabolites that are 
otherwise inaccessible for the host. Dietary polysaccharides, including cellulose, 
hemicellulose, resistant starches, and plant-derived pectin, are examples of these 
otherwise inaccessible nutrients; gut microbes can ferment dietary 
polysaccharides into short-chain fatty acids (SCFAs), mainly acetate, butyrate, 
and propionate, and at the same time elevate the absorption of monosaccharides 
(Bäckhed et al., 2004, Sonnenburg & Sonnenburg, 2014). In addition, gut 
microbes are able to ferment dietary proteins, transform complex plant 
phytochemicals into simpler metabolites, and convert primary bile acids into 
secondary bile acids (Louis et al., 2014, Sonnenburg & Bäckhed, 2016). The end 
products of microbial metabolism can serve as energy supplies for the host 
metabolism as well as signaling molecules (Tremaroli & Bäckhed, 2012, 
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Sonnenburg & Bäckhed, 2016). SCFAs, for instance, are important regulatory 
molecules that can act as histone deacetylase inhibitors or signal through G-
protein-coupled receptors (Louis et al., 2014, Sonnenburg & Bäckhed, 2016). In 
addition, SCFAs are important energy sources for the host and they serve as 
substrates for host metabolic pathways such as gluconeogenesis (Sonnenburg & 
Bäckhed, 2016). Especially butyrate works as an important energy source for the 
colonocytes, and it has been associated with alleviated intestinal inflammation 
and improved gut epithelial integrity (Hamer et al., 2009). Elevated SCFA 
production, however, may also lead to excess energy absorption and thus 
predispose to obesity, and therefore it has been suggested that SCFA-producing 
gut microbes may have an important role in the host energy metabolism 
(Bäckhed et al., 2004). Several studies have reported differences in the gut 
microbiota profiles between obese and lean individuals, supporting the idea that 
gut microbes may play a central role in the development of obesity and obesity-
related metabolic disorders (Cani & Delzenne, 2014, Stenman et al., 2015, 
Gérard, 2016). On the other hand, diet changes are able to rapidly modify the 
composition and metabolic functions of the gut microbiota (O’Keefe et al., 2015, 
Graf et al., 2015). Altogether, the metabolic capacity of the gut microbes is still 
relatively poorly understood, and gut microbes are likely to produce a vast 
number of metabolites whose functions or effects on human health still remain to 
be established (reviewed in Sonnenburg & Bäckhed, 2016). Comprehensive 
investigation is therefore required in order to determine the overall significance 
of the gut microbiota -derived metabolites and to more profoundly understand the 
functional host-microbe interactions (Tremaroli & Bäckhed, 2012, Wu et al., 
2015). 
2.1.2 Gut barrier function and intestinal dysbiosis 
Intestinal epithelium is in a close and constant contact with the gut microbiota. 
The gut epithelium possesses various mechanisms to restrain bacterial growth, to 
prevent bacterial adhesion, and to block the dissemination of the microbes and 
microbial toxins into underlying tissues (Ohland & Macnaughton, 2010, Muniz 
et al., 2012). These defense mechanisms include, for example, a stratified 
mucous layer that covers the intestinal epithelial cells, pattern-recognition 
receptors of the epithelial cells, antimicrobial peptides (AMPs) secreted by 
Paneth cells, secretory immunoglobulin A (IgA), and epithelial junctional 
complexes that regulate the permeability between the epithelial cells (Figure 1a). 
The purpose of this intestinal barrier is, in addition to protecting the host from the 
invasion of bacterial pathogens, to restrain uncontrolled inflammatory responses 
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and to maintain a balanced immunological state, i.e. homeostasis, in the gut 
(McGuckin et al., 2009, Muniz et al., 2012). 
Alongside the host factors, commensal gut bacteria play a key role in maintaining 
the gut homeostasis and preventing the colonization of pathogenic microbes 
(Chow et al., 2010, Belkaid & Hand, 2014). Commensal gut microbes are 
constantly interacting with the host innate immune system by providing 
immunological signals to the intestinal epithelial cells (Cerf-Bensussan & 
Gaboriau-Routhiau, 2010, Hiippala et al., 2018). The epithelial cells express 
receptors for microbial-associated molecular patterns, and these receptors, 
including Toll-like receptors (TLRs) and NOD-like receptors, activate signaling 
cascades that regulate the proliferation of the epithelial cells as well as the 
production of AMPs (Cerf-Bensussan & Gaboriau-Routhiau, 2010, Muniz et al., 
2012). In addition, the signals from the commensal bacteria are able to activate 
cells of the adaptive immune system and, for example, induce the secretion of the 
protective IgA antibodies. AMPs as well as IgA modulate the gut microbiota and 
prevent the luminal microbes from crossing the epithelial barrier (Chow et al., 
2010, Cerf-Bensussan & Gaboriau-Routhiau, 2010, Muniz et al., 2012). This 
constant interaction between the commensal gut microbes and the host immune 
system maintains a so-called physiological inflammation in the gut and has a 
crucial role in maintaining the intestinal homeostasis (Figure 1b). 
 
Figure 1. Intestinal barrier function. In a healthy gut, a physical epithelial barrier, 
together with commensal gut microbiota and immunological feedback mechanisms, 
works efficiently in avoiding microbial invasion and excessive activation of the host 
immune responses (a). Certain external triggers disrupting the gut microbiota and the 
immune balance can, however, lead to increased bacterial adherence, epithelial damage, 
and elevated entry of bacteria or bacteria-derived endotoxins, along with other 
molecules, into the intestinal lamina propria (b). This physiological stage called 
dysbiosis affects the host immune system and promotes the onset of intestinal 
inflammation. Based on (Cerf-Bensussan & Gaboriau-Routhiau, 2010, Muniz et al., 
2012, Belkaid & Hand, 2014). 
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Even though an individual’s gut microbiota is believed to form a relatively stable 
community, gut microbes undergo continuous selective pressure and are 
susceptible to both exogenous and endogenous modification (Lozupone et al., 
2012, Lynch & Pedersen, 2016). Several external triggers, including dietary 
changes, medication, and changes in the physiological state of the host, can 
significantly alter the gut microbiota composition (Lynch & Pedersen, 2016, 
Falony et al., 2016, Zhernakova et al., 2016). Unfavorable alterations in the gut 
microbiota can cause disruption of the colonization resistance provided by the 
commensal bacteria, leading to a physiological state called dysbiosis (Figure 1b) 
that potentially results in a pathological inflammation and disease (Modi et al., 
2014, Graf et al., 2015). In a dysbiotic gut microbiota, the overall bacterial 
diversity is usually reduced, whereas the proportion of opportunistic pathogens 
such as endotoxin-producing γ-Proteobacteria is increased (Walker & Lawley, 
2013). Meanwhile, the abundance of phylum Firmicutes, including several 
important SCFA-producers, is typically reduced (Walker & Lawley, 2013). 
SCFAs are important energy sources for the colonocytes and the reduced SCFA 
production may thus disrupt epithelial integrity. Consequently, gut microbiota 
dysbiosis predisposes the host to metabolic endotoxemia (discussed in Chapter 
2.3.3) and systemic inflammation. Accordingly, GI tract microbiota dysbiosis has 
been associated with several diseases and disorders, including obesity 
(Turnbaugh et al., 2008, Cani & Delzenne, 2014, Stenman et al., 2015, Gérard, 
2016), diabetes (Davis-Richardson et al., 2014, Endesfelder et al., 2014, Miele et 
al., 2015), rheumatoid arthritis (Eerola et al., 1994, Vaahtovuo et al., 2008, 
Sandhya et al., 2016), and inflammatory bowel disease (IBD) (Sokol et al., 2006, 
Muniz et al., 2012, Becker et al., 2015). The use of antimicrobial drugs is a 
common example of an external trigger that is capable of significantly decreasing 
the gut microbiota diversity and this way predispose the host to intestinal 
infections (reviewed in Modi et al., 2014). Simultaneously with constant rise in 
global antibiotic consumption (Friedrich, 2018), an increasing number of studies 
are illustrating the impact of antibiotic-induced gut microbiota alterations on 
human health (reviewed in Francino, 2016). Altogether, a homeostatic state in 
the human gut seems to require constant interaction and delicate balance between 
the commensal gut bacteria and the host, and disturbances of the gut microbiota 
can even lead to comprehensive immune dysfunction or autoimmunity (reviewed 
in Fung et al., 2012 and Honda & Littman, 2016). 
2.1.3 Faecalibacterium prausnitzii 
One of the most interesting members of gut microbiota is Faecalibacterium 
prausnitzii (F. prausnitzii), which is the only identified representative of genus 
 Review of literature 19 
Faecalibacterium. F. prausnitzii is one of the most abundant bacteria in the gut 
of several vertebrates, including human (Suau et al., 2001, Miquel et al., 2014), 
swine (Haenen et al., 2013, Foditsch et al., 2014), bovine (Oikonomou et al., 
2013, Foditsch et al., 2014), and chicken (Lund et al., 2010). F. prausnitzii 
belongs to Clostridium leptum (C. leptum) cluster, which further resides under 
phylum Firmicutes. Morphologically, F. prausnitzii is a non-motile and non-
spore-forming rod of size 0.5 - 0.8 × 2.0 - 14.0 µm (Duncan et al., 2002). The 
genome length of the bacterium is approximately 3.1 Mbp, and the G+C content 
of the DNA is around 56 % (Benevides et al., 2017). F. prausnitzii, as well as all 
other members of C. leptum cluster, is Gram-positive and strictly anaerobic 
(Lopez-Siles et al., 2012). The bacterium can, however, appear Gram-negative in 
staining, and as a matter of fact, F. prausnitzii was previously classified into 
Gram-negative Fusobacterium genus (Duncan et al., 2002). The classification 
and nomenclature were updated, since phylogenetic analyses revealed that the 
bacterium was obviously more related to Clostridia rather than Fusobacteria 
(Wang et al., 1996, Duncan et al., 2002). Based on 16S ribosomal RNA (rRNA) 
sequence analyses, F. prausnitzii species can be clustered into two or three 
phylogroups (Lopez-Siles et al., 2012, Martin et al., 2017). On the other hand, a 
recent pangenome analysis suggests that the phylogenetics of the species might 
be even more complex (Benevides et al., 2017). 
Functionally, F. prausnitzii is a highly active gut bacterium that appears to have 
beneficial impact on host health and physiology (Li et al., 2008, Miquel et al., 
2014, Miquel et al., 2015, Lopez-Siles et al., 2017). The bacterium, for example, 
possesses anti-inflammatory properties by inhibiting the production of pro-
inflammatory cytokines interleukin (IL)-12 and interferon γ, and by increasing 
the production of anti-inflammatory IL-10 (Sokol et al., 2008, Qiu et al., 2013). 
Recently, a Microbial Anti-Inflammatory Protein (MAM), secreted by F. 
prausnitzii, has been identified (Quévrain et al., 2016), and this bioactive 
molecule is suggested to reduce inflammation by blocking nuclear factor (NF)-
κB pathway and by regulating the cytokine production (Quévrain et al., 2016, 
Breyner et al., 2017). Further, metabolites like salicylic acid may be involved in 
the anti-inflammatory effects of the bacterium (Miquel et al., 2015). In addition 
to the regulation of cytokine production, F. prausnitzii is suggested to enhance 
intestinal barrier function by affecting the paracellular permeability of the gut 
epithelium (Carlsson et al., 2013, Martin et al., 2015). One probable link between 
the bacterium and the enhanced gut barrier function is the SCFA butyrate; F. 
prausnitzii is one of the main butyrate producers in the gut, and in humans, 
reduced intestinal F. prausnitzii abundance has been associated with low fecal 
butyrate concentration (Duncan et al., 2004, Benus et al., 2010). Butyrate is the 
preferred energy source for gut epithelial cells, and it is known to maintain 
favorable intestinal barrier function and to decrease oxidative stress (Hamer et 
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al., 2008, Hamer et al., 2009). In addition, butyrate regulates cell proliferation 
and differentiation, and is suggested to protect against colorectal cancer 
(Bradburn et al., 1993, Archer et al., 1998, Siavoshian et al., 2000). Along with 
butyrate, F. prausnitzii hydrolyzes starch, inulin, and various fructo-
oligosaccharides, which are all known to possess health-beneficial properties for 
the gut (Duncan et al., 2002). 
Reduction in F. prausnitzii abundance has been associated with several human 
diseases and disorders, including obesity (Hippe et al., 2016), metabolic 
disorders (Munukka et al., 2012), IBD (Sokol et al., 2009, Lopez-Siles et al., 
2016), and colorectal cancer (Lopez-Siles et al., 2016). In addition, low F. 
prausnitzii abundance has been linked to high liver fat content (Munukka et al., 
2014) and non-alcoholic steatohepatitis (NASH) (Wong et al., 2013). 
Furthermore, F. prausnitzii and its culture supernatant have been shown to 
ameliorate intestinal inflammation in murine models (Martin et al., 2014, Martin 
et al., 2015, Huang et al., 2016, Miquel et al., 2016). Due to the numerous 
beneficial properties of F. prausnitzii, it has been proposed that the bacterium 
could serve as biomarker to assist in the diagnostics of gut disorders and/or act as 
a next-generation probiotic supplement in the treatment of patients with the 
above-mentioned disorders and diseases (Lopez-Siles et al., 2017, Martin et al., 
2017). However, the metabolic activities of F. prausnitzii have been shown to 
vary between the different strains of the bacterium (Martin et al., 2017), 
suggesting that the anti-inflammatory capacities may not be equal between 
different strains. This within-species variation may set challenges on drawing 
conclusions from the association studies, as the species phylogroups are usually 
not determined in gut microbiota composition studies. 
2.1.4 Enterobacter cloacae 
Enterobacter cloacae (E. cloacae) is a facultative anaerobic gut bacterium 
belonging to family Enterobacteriaceae and genus Enterobacter. 
Morphologically, enterobacteria are Gram-negative, non-spore-forming rods of 
size 0.6 - 1.0 × 1.2 - 3.0 µm (Gaston, 1988). E. cloacae is a motile bacterium 
with peritrichous flagella (Hormaeche & Edwards, 1960, Keller et al., 1998), and 
as all members of the genus Enterobacter, it is an endotoxin-producing 
bacterium (Sanders & Sanders, 1997). The genome length of the type strain of 
the bacterium, E. cloacae subspecies cloacae ATCC® 13047™, is approximately 
5.3 Mbp, and the G+C content of the DNA is 54.7 % (Ren et al., 2010). E. 
cloacae belongs to normal human gut microbiota, but as an opportunistic 
pathogen, it can also cause a wide range of infections, including urinary tract 
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infections, bacteremia, and intra-abdominal infections (Sanders & Sanders, 1997, 
Lee et al., 2002). E. cloacae is naturally resistant to amoxicillin and 
cephalosporins, as it produces chromosomally encoded beta-lactamases (Bush et 
al., 1995). Interestingly, the abundance of Enterobacteriaceae family has been 
shown to increase in the gut microbiota of patients with NASH or liver cirrhosis 
(Lu et al., 2011, Chen et al., 2011, Özkul et al., 2017). 
Intestinal abundance of E. cloacae has been linked to obesity (Fei & Zhao, 2013, 
Yan et al., 2016). In a case study by Zhao and co-workers, a significant weight 
loss of a morbidly obese individual was associated with substantial decrease in 
the intestinal E. cloacae B29 load and significant reduction in serum endotoxin 
levels (Fei & Zhao, 2013). Furthermore, the same E. cloacae strain, isolated from 
the patient, was shown to initiate obesity and to induce significant changes in 
colon gene expression profiles when introduced to HFD fed germ-free (GF) 
mice, i.e. mice that lack normal microbiota (Fei & Zhao, 2013, Yan et al., 2016). 
However, neither HFD nor E. cloacae B29 alone seems to induce obesity or 
cause significant gene-expression alterations in the GF mice (Bäckhed et al., 
2007, Yan et al., 2016). Even though the GF mice are not the most optimal model 
to study the functions of the gut microbes (discussed in chapter 2.4.1), these 
results indicate that certain endotoxin-producing microbes and HFD may possess 
a synergistic effect that, possibly through an endotoxin-induced mechanism, 
contributes to the development of obesity (Fei & Zhao, 2013, Yan et al., 2016). 
2.2 Methods to study gut microbiota 
In the past decades, associations between gut microbiota and human diseases 
have been of great interest. In fact, gut microbiota is suggested to serve as an 
important potential target for future clinical diagnostics and personalized medical 
treatments (Guinane & Cotter, 2013, Lynch & Pedersen, 2016). The methods to 
study the gut microbiota composition and functions have advanced significantly 
during the past decades, but still to date, no clear consensus has been reached on 
the most optimal approaches to be utilized in the gut microbiota research (Lepage 
et al., 2013, Morgan & Huttenhower, 2014, Franzosa et al., 2014, Fournier et al., 
2015, Lagier et al., 2016). 
2.2.1 Traditional methods and ‘culturomics’ 
Bacterial identification from stool samples has traditionally rested upon bacterial 
cultivation on selective culture media, morphological examination, and 
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biochemical testing. These methods are still useful when searching for individual 
pathogens, for example when identifying the causing agent for gastroenteritis. 
However, the traditional identification methods are not optimal for 
comprehensive gut microbiota analysis, as most intestinal bacteria are obligate 
anaerobes that require specific culture conditions and complex media to grow in 
vitro (reviewed in Rajilić-Stojanović et al., 2007). Furthermore, the nutritional 
and environmental requirements of all gut bacteria have not been determined to 
date, and thus the currently available sample collection and culture methods may 
not be adequate for successful cultivation of all bacterial species residing in the 
gut (Browne et al., 2016, Lagier et al., 2016). In addition, the culture-based 
methods are relatively time-consuming and laborious (Lagier et al., 2015a). 
Therefore, high-throughput culture-based gut microbiota profiling would require 
new advancements in sample collection, storage, and culture methods (Lagier et 
al., 2015b, Browne et al., 2016). 
During the past decade, identification by matrix-assisted laser 
desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry has 
significantly speeded up the identification of the cultivated bacteria, as the use of 
MALDI-TOF mass spectrometry has suppressed the need for Gram staining and 
biochemical methods in the identification process (Lagier et al., 2016). 
Consequently, the culture-based bacterial isolation has become slightly more 
practicable, and Raoult and co-workers have introduced a concept of 
‘culturomics’, a culture-based approach for gut microbiota composition analysis 
where diverse culture conditions are accompanied by bacterial identification with 
MALDI-TOF mass spectrophotometry and 16S rRNA gene sequencing (Lagier 
et al., 2012, Lagier et al., 2015a). Culturomics is a bacterial isolation strategy 
where the culture conditions are adjusted and diversified in order to mimic the 
natural conditions of the GI tract (Fournier et al., 2015, Lagier et al., 2015b). By 
utilizing an extremely wide variety of different culture conditions, over a 
thousand different prokaryotic species have already been isolated from the 
human gut, including several novel bacterial species (Lagier et al., 2016). 
Nevertheless, the culturomics approach is extremely labor-intensive and time-
consuming; Raoult et al. have themselves reported that the identification of 1057 
bacterial species has required cultivation and analysis of over 900 000 bacterial 
colonies (Lagier et al., 2016). Even though the tested culture conditions have 
been standardized and ranked (Lagier et al., 2016), sufficient mimicking of the 
gut habitat still requires an enormous variation of different culture conditions, 
thus demanding time and resources. Therefore, average microbiology 
laboratories are not easily adapted for the application of these methods. 
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2.2.2 Molecular methods 
In the past decades, in both diagnostics and research, the traditional culture-based 
methods have for the most part been substituted, or at least complemented, by 
culture-independent molecular methods (Turnbaugh et al., 2007, Hamady & 
Knight, 2009, Costello et al., 2009). The molecular biology -based methods do 
not require viable bacteria, as the detection and quantification of the microbes is 
based on isolation and identification of the molecular fingerprints rather than 
viable organisms. The study of genetic material extracted directly from a defined 
environment or ecosystem is referred to as metagenomics, and the genetic 
catalog of the gut microbiota is called gut microbiome (Turnbaugh et al., 2007, 
Lepage et al., 2013). The molecular methods are often less time-consuming and 
more specific than the traditional cultivation-based methods in studying complex 
microbial communities, and consequently, metagenomics has become the method 
of choice for investigating the structure and functions of the gut microbiota 
(Lepage et al., 2013, Zhang et al., 2018). Further, as recent methodological 
improvements have enabled significant decreases in analysis costs, the basic 
molecular methods are no longer dramatically expensive as compared to the 
traditional methods. Metagenomics has vastly expanded the knowledge and 
understanding of the GI tract microbiome, and different molecular methods are 
increasingly used in studying the host-microbe interactions and the metabolic 
activities of the gut bacteria (Navas-Molina et al., 2013, Lepage et al., 2013, 
Kundu et al., 2017).  
2.2.2.1 16S rRNA gene amplification and sequencing 
16S rRNA, referring to the 16S small subunit ribosomal RNA, is a component of 
the small (30S) subunit of the prokaryotic ribosome (Stern et al., 1989). 16S 
rRNA encoding genes are present in all bacteria and archaea, but the copy 
number of the gene varies between organisms (Lee et al., 2008). The length of 
the microbial 16S rRNA gene in approximately 1500 bp. Certain regions of the 
gene are highly conserved between the microbial species and have an extremely 
slow evolutionary rate (Van de Peer et al., 1996). In addition to these highly 
conserved gene regions, the 16S rRNA gene generally includes nine 
hypervariable regions (V1-V9; Figure 2) that possess significant sequence 
dissimilarity between distinct microbial species (Van de Peer et al., 1996, 
Chakravorty et al., 2007). Due to these properties, the 16S rRNA gene serves as a 
valuable tool for phylogenetic and taxonomic analyses, along with species 
identification, of the micro-organisms (Van de Peer et al., 1996, Chakravorty et 
al., 2007, Zhang et al., 2018). In fact, 16S rRNA sequencing has been one of the 
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most commonly used methods in bacterial classification and species 
identification since the late 1990s. The length of each 16S rRNA gene 
hypervariable region is about 30 to 100 bp, being thus well suited for PCR 
amplification and other molecular biology techniques (Van de Peer et al., 1996). 
On the other hand, the degree of sequence diversity varies between the variable 
regions, and none of the hypervariable regions is alone adequate for species-
specific identification of all bacteria (Chakravorty et al., 2007). Therefore, 
analysis of the full-length 16S rRNA gene is required for most comprehensive 
and reliable bacterial species identification (Chakravorty et al., 2007). 
 
Figure 2. 16S rRNA of Escherichia coli. The 16S rRNA secondary structure has been 
adapted from XRNA gallery (http://rna.ucsc.edu/rnacenter/xrna/xrna_gallery.html). The 
hypervariable regions (V1-V9) are highlighted based on (Chakravorty et al., 2007). 
One of the first 16S rRNA -targeting methods utilized in gut microbiota research 
was the amplification of the bacterial 16S rRNA encoding gene by polymerase 
chain reaction (PCR) using species/group specific primers (reviewed in Lepage 
et al., 2013). Real-time quantitative PCR (qPCR) with carefully designed primers 
enables both identification and quantification of the targeted bacterial species or 
groups, but the identification is restricted to the targeted bacteria while no 
information about the overall bacterial composition is obtained. Techniques that 
target the bacterial 16S rRNA gene and other genetic markers have, however, 
significantly proceeded during the past few decades. Especially the next 
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generation sequencing (NGS) of the 16S rRNA gene has become a universally 
accessible method for determining the 16S rRNA profiles of the GI tract 
microbiota. In next-generation 16S rRNA gene sequencing, one or several 
hypervariable regions of the bacterial 16S rRNA gene are amplified, and the 
sequences from each original sample are identified using sample-specific index 
sequences (Klindworth et al., 2013). Then, the 16S rRNA gene libraries are 
sequenced with a high-throughput instrument, e.g. Illumina MiSeq (Illumina, 
Inc., San Diego, CA, USA) or Ion Torrent (Thermo Fischer Scientific, Waltham, 
MA, USA), and the sequence data analysis is performed with specific 
bioinformatic analysis tools. Briefly, the sequences are trimmed and clustered, 
and then compared to known sequences in reference databases, e.g. Greengenes 
(DeSantis et al., 2006) or SILVA (Quast et al., 2012). Amplification with 
universal primers, accompanied by NGS, enables fast and high-throughput 
analyses of complex microbial communities, while sample identification 
advancements and high-throughput sequencing instruments allow analyses of 
several specimens simultaneously. These methodological advancements have led 
to a significant decrease in the sequencing costs, making the 16S rRNA gene 
sequencing readily feasible in the gut microbiota research (Tringe & Hugenholtz, 
2008, Hamady & Knight, 2009, Mandal et al., 2015). Ever since the introduction 
of the 16S rRNA gene targeting NGS, the knowledge on the composition of the 
gut microbiota has greatly expanded (Tringe & Hugenholtz, 2008, Costello et al., 
2009, Qin et al., 2010). 
2.2.2.2 Limitations of the 16S rRNA gene sequencing 
While the 16S rRNA gene sequencing has become more cost-effective and thus 
more readily available, it has also become increasingly evident that the molecular 
methods have weaknesses; several studies have emphasized that all metagenomic 
analyses are prone to severe biases (Cai et al., 2013, Kennedy et al., 2014, 
Brooks et al., 2015). The first potential cause for bias in the 16S rRNA gene 
sequencing, as in all molecular techniques, is the sample collection and pre-
processing. Sample material in gut microbiota studies usually consist of stool 
samples, rectal swabs, or endoscopic biopsies, and as the bacterial ecosystem in 
these samples is extremely complex, an inconsiderate sample collection or 
storage can have a significant impact on the study results (Salonen et al., 2010, 
Maukonen et al., 2012). For example, sample freezing has been reported to 
substantially affect the observed Firmicutes-to-Bacteroidetes ratio (Bahl et al., 
2012). It is therefore outstandingly important that all samples in one study are 
collected and stored identically, applying methods that minimize the risk of 
alterations in the microbial composition prior to downstream analyses 
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(Maukonen et al., 2012). The second critical step in gut microbiota studies is the 
DNA extraction; DNA isolation method has been proposed to significantly affect 
the results of the NGS analyses (Maukonen et al., 2012, Wesolowska-Andersen 
et al., 2014, Burbach et al., 2016). For example, the ratio between observed 
Gram-positive and Gram-negative bacteria may vary significantly depending on 
the applied DNA extraction protocol, as the cell wall of Gram-positive bacteria is 
notably stronger and more difficult to lyse than the cell wall of Gram-negative 
bacteria (Costea et al., 2017). It has been generally acknowledged that rigorous 
lysis, e.g. adequate bead-beating, is required in order to successfully extract DNA 
from certain Gram-positive bacteria such as Bifidobacterium (Maukonen et al., 
2012, Santiago et al., 2014, Walker et al., 2015). 
In addition, the NGS results are highly dependent on the analysis methods 
themselves; for example, the targeted 16S rRNA gene region and the sequencing 
platform have been shown to significantly influence the outcome of the gut 
microbiota composition studies  (Wang et al., 2007, Liu et al., 2008, Klindworth 
et al., 2013, Starke et al., 2014, Tremblay et al., 2015, Fouhy et al., 2016). And 
further, the sequence data analysis methods can affect the result output (Hamady 
& Knight, 2009, Bokulich et al., 2013, Weiss et al., 2017). And in addition to the 
method-dependent biases, another important frailty in the 16S rRNA gene 
sequencing based gut microbiota analyses is the limited sequencing depth of the 
current NGS techniques (Jovel et al., 2016). As molecular methods can identify 
bacterial species that are not cultivable in vitro, they are often considered 
extremely sensitive. It has, however, been reported that the existing 16S rRNA 
gene sequencing methods are actually not optimal for acknowledging bacteria at 
low concentrations, and because of this, several bacterial species/genera that 
present abundances below the detection threshold, yet still potentially possess 
clinical importance, may be missed (Lagier et al., 2012). Increased sequencing 
depth, on the other hand, predisposes to external contamination and sequencing 
artifacts (Jovel et al., 2016). Thus, research performed with the current 16S 
rRNA gene sequencing methodologies must compromise between the detection 
threshold and the risk of false findings among the detected taxa. For these 
reasons, reliable comparison of different 16S rRNA gene based NGS studies 
remains a challenge (Hamady & Knight, 2009). 
16S rRNA gene sequencing based methods provide relative rather than absolute 
quantification of the bacteria, and even though certain predictive functional 
analysis packages are available (Langille et al., 2013, Aßhauer et al., 2015), no 
specific conclusions about the functions of the gut microbiota should be made 
solely based on 16S RNA gene profiles. In addition, due to limited sequencing 
length, differentiation of closely related bacterial species is deficient with the 
currently available 16S rRNA based NGS methods; bacteria from same genera 
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often obtain close to identical sequences across the region that can be sequenced 
at once (Chakravorty et al., 2007). Therefore, even though the 16S rRNA based 
NGS analysis is a valuable tool in gut microbiota composition analyses, its 
obvious weakness is the low taxonomic resolution (Jovel et al., 2016, Ranjan et 
al., 2016). There has recently been significant progress in the development of 
technologies providing longer sequencing reads, and these methods may provide 
a solution for this issue as they enable full-length 16S rRNA gene sequencing 
(Bleidorn, 2016, van Dijk et al., 2018). At present, the general use of these long-
read sequencing technologies is limited due to high cost and relatively high 
sequencing error rates (Goodwin et al., 2016, Bleidorn, 2016). Consequently, in 
recent years, 16S rRNA gene sequencing has been increasingly substituted by 
more comprehensive analysis methods, mainly metagenomic shotgun sequencing 
(Table 2). However, as shotgun sequencing is noticeably more expensive and 
requires more hardware resources, 16S rRNA gene sequencing is still often the 
method of choice for the analysis of gut microbiota composition in large sample 
cohorts (Jovel et al., 2016). 
2.2.2.3 Shotgun metagenome sequencing, shotgun metatranscriptome 
sequencing, metaproteomics, and metabolomics 
In shotgun sequencing, instead of generating and sequencing amplicon libraries 
of 16S rRNA gene or some other specific gene target, the whole DNA or RNA 
(cDNA) content of the sample is sequenced in short reads and then analyzed 
based on comparison with sequence databases (reviewed in Lepage et al., 2013). 
DNA-targeting shotgun sequencing of a complex microbial ecosystem is referred 
to as shotgun metagenome sequencing. Shotgun metagenome sequencing can be 
used for bacterial taxonomic assignment, but also for screening certain genes 
and/or gene sets in a microbial ecosystem (Morgan & Huttenhower, 2014). It is 
able to provide information about e.g. metabolic and functional capability of the 
microbiome, which is an important advantage in comparison to the 16S rRNA 
based NGS that provides information merely on the bacterial composition and 
diversity (Table 2; Jovel et al., 2016). Consequently, shotgun metagenome 
sequencing is an increasingly popular method in the gut microbiota research. In 
addition to studying complex microbial ecosystems, the method can also be used 
for reconstructing whole genome sequences of single bacteria, being thus useful 
for analyzing bacterial genomes from pure cultures (Fleischmann et al., 1995). 
As long as decent sequencing depth is acquired, shotgun metagenome sequencing 
provides significant information about the microbial composition and overall 
gene content of the bacterial ecosystems (Ranjan et al., 2016). Nevertheless, the 
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method is not able to provide information about the actual activity of the 
observed genes (Franzosa et al., 2014), and metatranscriptomic, metaproteomic, 
or metabolomic applications are required for genuine functional analyses (Table 
2). Term ‘metatranscriptomics’ refers to the analysis of community-wide gene 
expression profiles of complex ecosystems (Bashiardes et al., 2016). While 
shotgun metagenome sequencing is targeting the ecosystem’s whole DNA, in 
shotgun metatranscriptome sequencing, the messenger RNA (mRNA) content of 
the ecosystem is analyzed (Morgan & Huttenhower, 2014, Bashiardes et al., 
2016). 
Table 2. Culture-independent approaches to study the human gut microbiota 
Approach Target & outcome Advantages and limitations 
16S rRNA gene 
sequencing 
Target: 16S rRNA gene 
 
Outcome: bacterial and 
archaeal composition 
and diversity 
+ Least expensive of the molecular methods 
+ High-throughput and relatively easy to perform 
+ Extensive reference databases available 
− Provided information is limited to taxonomic composition and 
microbial diversity 
− Reliable taxonomic resolution is limited to genus level 
− Does not distinguish between dead and alive bacteria 
− Does not provide information about viruses or eukarya 
− Method-dependent biases and batch effects due to sample storage, 
DNA extraction, PCR, and sequencing 
Shotgun 
metagenome 
sequencing 
Target: genomic DNA 
 
Outcome: bacterial, 
archaeal, fungal, and 
viral composition and 
overall gene content 
+ Enables bacterial species-level identification 
+ Besides taxonomic analyses, provides information about the 
functional capacity of the microbes 
− More expensive and laborious than amplicon sequencing 
− Requires extensive hardware capacity 
− Prone to similar biases as 16S rRNA gene sequencing 
− Does not provide information about the activity of the observed 
genes 
Shotgun meta-
transcriptome 
sequencing 
Target: cDNA prepared 
from microbial mRNA 
 
Outcome: bacterial, 
archaeal, fungal, and 
viral transcriptomes, i.e. 
gene expression  
+ Provides information about the actual gene activity 
+ Can be used for measuring functions and functional changes of 
the microbes under certain physiological / environmental 
conditions 
− Prone to biases caused by sample processing, as RNA is 
significantly less stable than DNA 
− mRNA represents only a minority of fecal RNA → rRNA and 
tRNA need to be removed before reverse transcription  
− Prone to host mRNA contamination 
− Requires extensive hardware capacity 
− More expensive and laborious than shotgun metagenome 
sequencing 
Meta-proteomics Target: proteins / 
peptides 
 
Outcome: intestinal 
protein profile 
+ Has potential to provide a view of microbial gene activity under 
certain psychological / environmental conditions 
− No standardized protocols available 
− Exclusion of host- or diet-derived proteins not feasible 
− Reference databases still incomplete 
− Requires extensive hardware capacity 
Metabolomics Target: metabolites 
 
Outcome: profile of the 
end products of 
microbial and host 
metabolism 
+ Can be performed as targeted or untargeted analyses 
+ Has potential to provide means for e.g. disease biomarker 
discoveries 
− No standardized protocols available 
− Discrimination between microbial and host metabolites not 
feasible 
− Reference databases still incomplete 
− Requires extensive hardware capacity 
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Shotgun metatranscriptome sequencing can provide information about the 
functions and functional changes of the intestinal ecosystem under certain 
conditions (Morgan & Huttenhower, 2014, Franzosa et al., 2014), and the 
method holds great promise in enhancing the understanding of the microbial 
functions and host-microbe interactions in different health-related conditions 
(Bashiardes et al., 2016). Consequently, shotgun metatranscriptome sequencing 
is increasingly used in gut microbiota research. However, the method holds 
several challenges that need to be acknowledged in the technical setup (Table 2), 
and besides making the method expensive and time-consuming, these special 
requirements make shotgun metatranscriptome sequencing extremely prone to 
biases. Therefore, the full potential of the methodology is yet to be harnessed in 
gut microbiome research (Morgan & Huttenhower, 2014). 
While metatranscriptomics examine the gene activity of the microbial ecosystem, 
metaproteomics and metabolomics are intended for providing information about 
the microbiome’s molecular activities (Table 2; Morgan & Huttenhower, 2014). 
Basically, gut metaproteomics refers to mapping and profiling of microbial 
proteins (reviewed in Petriz & Franco, 2017), while gut metabolomics refers to 
profiling of microbial, along with host, metabolites (reviewed in Vernocchi et al., 
2016). These methods hold promise, for example, in determining differences in 
protein production under certain physiological conditions. The methods are still 
in their infancy regarding the gut microbiome research, and no standardized 
protocols for the proteomic or metabolomics analyses of the intestinal microbes 
currently exist (Morgan & Huttenhower, 2014, Petriz & Franco, 2017). 
Nevertheless, both methods indisputably have great potential to provide valuable 
information concerning the biology of the intestinal microbial ecosystem, and 
methodological development is determinedly ongoing (Wilmes et al., 2015, 
Vernocchi et al., 2016, Petriz & Franco, 2017). 
2.2.3 Future aspects in gut microbiota research 
At the moment, the method development in the gut microbiota research field is 
extremely rapid. For example, several so-called third-generation sequencing 
protocols, enabling longer sequencing read lengths, are under constant 
development, and these methods are expected to provide a solution for some of 
the current weaknesses in the taxonomic analyses of 16S rRNA gene sequencing 
and shotgun sequencing (Bleidorn, 2016, van Dijk et al., 2018). Meanwhile, there 
is constant methodological progress in the metatranscriptomic, metaproteomic, 
and metabolomic approaches (Wilmes et al., 2015, Bashiardes et al., 2016, 
Matysik et al., 2016). And finally, the development of bioinformatic analysis 
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tools for gut microbiome research is continuous. Several open source software 
packages are already available for basic microbiome data analysis (Schloss et al., 
2009, Caporaso et al., 2010), but only few of the existing tools are adequately 
user-friendly for basic scientists with limited bioinformatic knowledge (Dhariwal 
et al., 2017). Further, in order to obtain a comprehensive view of the gut 
microbiota composition and functions, the taxonomic data, i.e. the 16S rRNA 
gene sequencing or shotgun metagenome sequencing data, should ideally be 
integrated with the functional data, i.e. the metatranscriptomic, metaproteomic, 
and/or metabolomic data, and this data integration requires the development of 
novel data analysis methods (Morgan & Huttenhower, 2014, Franzosa et al., 
2014). In fact, as the modern data analysis methods that allow adequate 
integration of the diverse meta-omics data are likely to require both extensive 
computational power and advanced bioinformatic tools, the future of gut 
microbiota research appears to largely lean on competent bioinformatic 
specialists (Franzosa et al., 2014, Jovel et al., 2016). 
While the molecular methods unquestionably have the potential to provide high-
resolution picture of the gut microbiota composition and the host-bacteria 
interactions, the culturomics strategy (discussed in Chapter 2.2.1) has also 
offered a great deal of new information concerning the prokaryotic inhabitants of 
the human gut (Sankar et al., 2015, Lagier et al., 2016). In fact, this so called 
renaissance of the bacterial culture has, to some extent, challenged the molecular 
biology methods in gut microbiota analysis, as in certain cases, culturomics seem 
to produce more comprehensive results than the metagenomic approaches 
(Dubourg et al., 2013, Lagier et al., 2015a). Further, it has been reported that the 
culture-based and molecular-based gut microbiota composition analyses tend to 
result in significantly divergent outcomes; it has been stated that only a minority 
of the bacterial species present in a human fecal sample can be detected with 
both culturomics and metagenomics (Lagier et al., 2012). Therefore, if method 
development led to further reduction in the required culture conditions, 
culturomics could provide a useful supplement to the molecular microbiology 
methods in the gut microbiota research and especially in the bacterial taxonomy 
assignment (Fournier et al., 2015, Sankar et al., 2015). Bacterial cultivation is 
still required for physiological characterization of the bacteria, and further, the 
molecular methods have not yet been able to replace culture-based methods in 
antibiotic susceptibility testing. It therefore appears that both bacterial cultivation 
and meta-omics are required for comprehensive understanding of the gut 
microbiota composition and function (Lagier et al., 2015a). 
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2.3 Obesity, metabolic disorders, and gut microbiota 
The worldwide prevalence of obesity has almost tripled since 1975 (World 
Health Organization, 2017). WHO has estimated that, in 2016, more than 1.9 
billion adults were overweight (BMI ≥ 25 kg/m2), and of these, over 650 million 
were obese (BMI ≥ 30 kg/m2). Overall, in 2016, approximately 13 % of the 
World’s adult population were obese. Obesity is generally defined as excessive 
fat accumulation that is a consequence of excess energy intake in comparison to 
energy consumption. Mechanistically, however, obesity is a complex metabolic 
disorder that often disrupts the overall metabolism of the body (Arora et al., 
2013). The excess energy intake leads to an induction of several metabolic 
cascades that aim at balancing the energy disequilibrium of the body. Thus, as a 
result of the increased prevalence of obesity, the burden of obesity-related 
metabolic disorders like T2D and NAFLD has also expanded. Clustering of 
several obesity-related conditions can be referred to as ‘metabolic syndrome’, 
which is a comprehensive disorder in energy distribution and storage (Kaur, 
2014). Visceral adiposity, IR, elevated blood pressure, and hyperglycemia are 
some of the several constituting factors of the syndrome. Metabolic syndrome 
significantly increases the risk of cardiovascular diseases and T2D (Kaur, 2014). 
On the other hand, all obese individuals do not develop metabolic syndrome. 
2.3.1 Insulin resistance 
Insulin is an important anabolic hormone that regulates the metabolism of 
carbohydrates, fats, and proteins. The main physiological stimulus for insulin 
synthesis is glucose; in a normal situation, body responses to high blood glucose 
level by inducing insulin secretion (Nelson & Cox, 2008). Insulin has several 
physiological effects, the most prominent being the induction of glucose intake 
by insulin sensitive organs such as adipose tissue and skeletal muscles. In the 
adipose tissue, insulin also plays an important role in maintaining a balance 
between fatty acid storage and the release of free fatty acids (FFAs) into the 
circulation, as insulin promotes triacylglycerol (TAG) synthesis and inhibits 
lipolysis, i.e. the breakdown of the lipids (Dimitriadis et al., 2011). In a normal 
physiological condition, adipose tissue is extremely sensitive to the blood insulin 
concentrations, whereas in obesity, the sensitivity of adipose tissue to respond to 
the blood insulin level is often decreased (Morigny et al., 2016). This state is 
called insulin resistance (IR), which is a condition that has been recognized in all 
insulin sensitive organs including adipose tissue, skeletal muscles, and liver 
(Nelson & Cox, 2008). IR predisposes the host to hyperglycemia, as the blood 
glucose is not normally absorbed by the cells. Subsequently, the insulin 
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production may also increase, resulting in blood hyperinsulinemia (Nelson & 
Cox, 2008). In general, IR is likely to affect the overall metabolism of the host. 
IR has been closely related to metabolic syndrome, and it is likely to contribute 
to the development of T2D (Nelson & Cox, 2008). The pathophysiology of IR 
during obesity, however, remains largely unknown. As well as obesity and T2D, 
IR has been strongly associated with the Western diet and sedentary lifestyle, and 
the condition is primarily treated by exercise and weight management (Kaur, 
2014).  
2.3.2 Non-alcoholic fatty liver disease 
Obesity is often, yet not always, accompanied by excess liver fat accumulation. 
NAFLD is a condition where more than 5 % of liver cells present steatosis, i.e. 
accumulation of TAGs, without excessive alcohol consumption (Marchesini et 
al., 2016). In practice, NAFLD represents a wide spectrum of conditions from 
relatively mild steatosis to severe non-alcoholic steatohepatitis (NASH). NAFLD 
is an increasingly common health condition, and currently the most prevalent 
liver disorder in the Western countries (Adams & Lindor, 2007). The disorder is 
already affecting 20-30 % of general population and up to 75-100 % of morbidly 
obese individuals, and the prevalence is continuously increasing (Henao-Mejia et 
al., 2013).  
The pathophysiology of NAFLD has not been fully elucidated, but the condition 
is strongly linked to obesity, metabolic syndrome, and IR (Adams & Lindor, 
2007, Lomonaco et al., 2012, Bril et al., 2017). Metabolically healthy obese 
individuals rarely have hepatic steatosis, which suggests that metabolic stress is 
likely to play an important role in the development of NAFLD. One possible 
reason for the metabolic stress is hepatic lipotoxicity, which refers to intracellular 
accumulation of harmful lipid products (Cusi, 2010, Lomonaco et al., 2012). 
Consequently, adipose tissue dysfunction and IR are proposed to play important 
roles in the development of lipotoxicity and hepatic steatosis in NAFLD 
(Lomonaco et al., 2012, Bril et al., 2017). Adipose tissue is the primary source of 
FFAs for hepatic TAG synthesis, and adipose tissue IR is suggested to result in 
excess TAG lipolysis that subsequently causes an oversupply of the FFAs into 
the liver. The excess FFA supply may then cause excess hepatic TAG synthesis 
and lipotoxicity, which leads to further impairment in the insulin signaling, along 
with activation of different inflammatory pathways (Cusi, 2010, Lomonaco et al., 
2012). 
NAFLD can be diagnosed by imaging, serum biomarkers, and histology. Imaging 
is currently preferred as the first-line diagnostic tool due to its noninvasive nature 
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(Marchesini et al., 2016). In ultrasonography, the hepatic steatosis is detected as 
an increase in echogenicity (Joseph et al., 1991). The method is reliable in 
detecting moderate to severe steatosis, but it has limited sensitivity in detecting 
mild steatosis. In addition, the method is not optimal for examining patients with 
high BMI (Fishbein et al., 2005, Adams & Lindor, 2007, Marchesini et al., 
2016). Further, ultrasonography is not reliable in the evaluation of the degree of 
steatosis, as the visual assessment is prone to significant inter-observer variability 
(Cengiz et al., 2014). Magnetic resonance imaging, by contrast, allows accurate 
quantitation of the liver fat content (Longo et al., 1995, Fishbein et al., 2005), but 
this method is not optimal for general screening in clinical practice due to 
relatively high cost and long imaging time (Marchesini et al., 2016). Mild to 
moderate elevation in serum AST, ALT, or both, is common in NAFLD patients, 
and often the only observed laboratory finding. Several serum biomarkers and 
index scores have been generated for predicting the presence and severity of 
NAFLD (Marchesini et al., 2016), but the validity of these indicators in disease 
diagnostics remains unclear (Sberna et al., 2018). Histology is still the best 
diagnostic tool for analyzing the severity of NAFLD, and liver biopsy is required 
in order to differentiate hepatic steatosis from NAFLD’s more severe form, 
NASH (Marchesini et al., 2016). 
Hepatic steatosis is usually a reversible condition that can be treated by lifestyle 
changes, i.e. weight loss via healthier diet and increased exercise (Lazo et al., 
2010, Jordy et al., 2015). Several agents, such as vitamin E and certain diabetes 
medications, have been tested in the treatment of NAFLD, but the results have 
been controversial (Marchesini et al., 2016). Therefore, in addition to lifestyle 
improvements, no approved prevention or treatment strategies for NAFLD 
currently exist. This is a problem in the developed countries, where people are 
accustomed to their unhealthy lifestyle including high-calorie diet and lack of 
exercise. In addition, most NAFLD patients are symptomless (Adams & Lindor, 
2007), which is likely to further decrease the motivation for lifestyle changes. As 
untreated NAFLD can progress into NASH, liver cirrhosis, or even 
hepatocellular carcinoma (Adams & Lindor, 2007), investigation of novel 
prevention and treatment strategies for the disease is increasingly important. 
2.3.3 Gut microbes in obesity and metabolic disorders 
A causal link between gut microbes and host metabolism was first proposed 
already over a decade ago, when mouse studies demonstrated that fecal 
microbiota transplantation from obese mice was able to replicate the obese 
phenotype in GF mice (Bäckhed et al., 2004, Turnbaugh et al., 2008). This 
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phenomenon may to be linked to the ability of gut microbes to process otherwise 
indigestible dietary nutrients and, consequently, increased deposition of extracted 
energy (Bäckhed et al., 2004). Accordingly, in both humans and mice, the gut 
microbiota of obese individuals has been shown to differ from the microbiota of 
lean individuals (Ley, 2010, Gérard, 2016). The reports regarding the gut 
microbiota composition in obesity have, however, been rather inconsistent. For 
example, findings regarding the abundance of phyla Firmicutes and 
Bacteroidetes have been highly discordant (Bäckhed et al., 2004, Ley et al., 
2005, Duncan et al., 2008, Schwiertz et al., 2010, Raman et al., 2013). 
Obesity is often associated with low-grade inflammation, which has been 
suggested to further contribute to IR, T2D and other metabolic disorders (Makki 
et al., 2013, Piya et al., 2013). Mouse studies have demonstrated that diet-
induced obesity, i.e. obesity developed in response to HFD, is associated with an 
increased secretion of pro-inflammatory cytokines (Xu et al., 2003, Ding et al., 
2010). Microbial endotoxins have been put forward as one possible underlying 
stimuli for the immunological functions and metabolic rearrangements associated 
with obesity; endotoxins, such as lipopolysaccharides (LPS), may possess 
capability to induce inflammation and adverse metabolic effects on the host 
(Cani et al., 2007, Kopp et al., 2009, Könner & Brüning, 2011). LPS is the major 
component of the outer membrane of Gram-negative bacteria and known to cause 
inflammation when ending up in the circulation (Beutler & Rietschel, 2003, Brun 
et al., 2007, Amar et al., 2011). The main pattern recognition receptor for LPS is 
Toll-like receptor 4 (TLR4) that, likely as a complex with MD-2, is present on 
the surface of several immune cells and various other cell types, including 
adipocytes and hepatocytes (Lu et al., 2008, Boutagy et al., 2016). The 
recognition of LPS by TLR4 initiates an activation of multiple signaling 
components, such as NF-κB, and subsequent production of pro-inflammatory 
cytokines that further activate the innate immune system (Cani et al., 2007, Lu et 
al., 2008, Boutagy et al., 2016). The binding of LPS to the TLR4-MD-2 complex 
is preceded by an activation of a co-receptor CD14, to which LPS is presented by 
LPS-binding protein (Lu et al., 2008). CD14 is present on the membrane of 
several TLR4-presenting cells, but also in a soluble form (Lu et al., 2008). 
In mice, increased energy intake, e.g. due to HFD, is suggested to increase gut 
permeability and to cause systemic, low-level increase in the plasma LPS levels 
(Cani et al., 2007, Brun et al., 2007). While severe systemic infections often 
cause over a hundred-fold increase in the circulating endotoxin concentration 
compared to healthy individuals (Opal et al., 1999), the endotoxemia level 
induced by HFD is considerably lower; in mice, HFD has been demonstrated to 
induce approximately 2- to 4-fold increase in the concentration of circulating 
LPS (Cani et al., 2007, Brun et al., 2007). This low-grade elevation in the plasma 
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LPS level has been hypothesized to serve as a possible mediator of metabolic 
imbalance observed in obesity, as it has been associated with elevated body 
weight, adipose tissue and liver weight, increased pro-inflammatory cytokine 
levels, and fasted hyperglycemia and insulinemia (Cani et al., 2007, Brun et al., 
2007). Due to the possible link between the low-level endotoxemia and 
metabolic disorders, the condition has been termed ‘metabolic endotoxemia’ 
(Cani et al., 2007). Recently, gut microbiota dysbiosis has been strongly linked to 
gut permeability and obesity-associated low-grade inflammation (Sekirov et al., 
2010, Modi et al., 2014, Graf et al., 2015, Becker et al., 2015). Therefore, it 
seems evident that certain gut microbes - especially the endotoxin-possessing 
bacteria - could induce the metabolic endotoxemia and, consequently, contribute 
to the development of obesity and obesity-linked metabolic diseases (Cani et al., 
2007, Sekirov et al., 2010). This hypothesis is reinforced by the fact that GF mice 
are immune to the diet-induced obesity and IR (Bäckhed et al., 2007, Ding et al., 
2010). Profound studies are, however, needed in order to elucidate the 
mechanism underlying the initiation of the obesity-associated inflammatory 
cascades. 
In addition to obesity and IR, NAFLD has also been associated with intestinal 
dysbiosis and the abundance of certain gut microbes (Miele et al., 2009, Zhu et 
al., 2013, Raman et al., 2013, Munukka et al., 2014, Boursier et al., 2016, Shen et 
al., 2017). For example, subjects with NAFLD have been reported to obtain 
increased gut permeability (Miele et al., 2009) and elevated abundance of 
intestinal Enterobacteriaceae (Zhu et al., 2013, Özkul et al., 2017, Shen et al., 
2017). On the other hand, low F. prausnitzii (Munukka et al., 2014) and 
Akkermansia muciniphila (Özkul et al., 2017) abundances have been reported in 
NAFLD patients compared to healthy individuals. Both F. prausnitzii and A. 
muciniphila are believed to support epithelial integrity and gut health (Martin et 
al., 2014, Schneeberger et al., 2015, Reunanen et al., 2015), whereas certain 
Enterobacteriaceae genera have been associated with metabolic endotoxemia 
(Yan et al., 2016). Meanwhile in mice, gut microbiota composition has been 
demonstrated to contribute to liver fat accumulation even independently of diet 
and obesity (Le Roy et al., 2013). As the GI tract is connected to the liver via 
hepatic portal system, liver is well exposed to the intestinal molecules and 
metabolites (Abu-Shanab & Quigley, 2010). Therefore, in the case of leaky gut, 
i.e. increased gut permeability, the translocated bacteria, bacterial endotoxins, 
and other molecules originating from the gut may be capable of directly inducing 
the hepatic fat accumulation (Figure 3; Henao-Mejia et al., 2013, Leung et al., 
2016, Tilg et al., 2016). On the other hand, results of some studies propose that 
adipose tissue inflammation may be the link between the intestinal dysbiosis and 
NAFLD (Munukka et al., 2014, Pekkala et al., 2015). The underlying 
mechanisms, however, remain to be determined. 
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Figure 3. Gut microbiota dysbiosis -related mechanisms that may contribute to 
hepatic fat accumulation. Gut-liver axis is proposed to play a role in the progression of 
hepatic steatosis and non-alcoholic fatty liver disease (NAFLD). Gut microbiota 
dysbiosis disrupts the gut barrier function and leads to an increased gut permeability, 
i.e. leaky gut, which allows an excess flux of bacteria, bacterial toxins, and bacterial 
fragments (e.g. endotoxins) from the gut lumen (Leung et al., 2016). This causes 
metabolic endotoxemia and immune dysfunction that can induce liver inflammation and 
NAFLD. Meanwhile, dysbiotic gut microbiota typically represents decreased short-
chain fatty acid (SCFA) production due to low abundances of Firmicutes. As SCFAs 
regulate hepatic lipid metabolism, SCFA depletion may cause excess hepatic 
lipogenesis and reduced β-oxidation that increase the accumulation of free fatty acid in 
liver (Tilg et al., 2016). In addition, intestinal dysbiosis is suggested to associate with 
reduced choline availability, which can cause decreased synthesis and secretion of 
VLDLs from the liver and thus further induce the hepatic steatosis (Abu-Shanab & 
Quigley, 2010). Gut microbiota dysbiosis can also increase the endogenous production 
of volatile organic compounds (VOCs) such as ethanol due to increased abundances of 
Proteobacteria (Leung et al., 2016). VOCs may contribute to liver injury and NAFLD 
progression by further increasing the intestinal permeability and consequently triggering 
the metabolic endotoxemia. In addition, VOCs may have direct toxic effects on the liver 
(Leung et al., 2016). Proposedly several of these mechanisms are involved in the 
progression of NAFLD, but the pathways may vary between individuals. 
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2.3.4 Methods to study the role of gut microbes in obesity and metabolic 
disorders 
The first groundbreaking findings regarding the possible causality between gut 
microbiota and obesity were drawn from studies where initially GF mice were 
colonized with gut microbiota from conventionally bred mice (Bäckhed et al., 
2007, Turnbaugh et al., 2008). In these studies, as already mentioned above, GF 
mice were shown to be resistant to diet-induced obesity, whereas colonization 
with gut microbiota resulted in significant weight gain (Bäckhed et al., 2007, 
Turnbaugh et al., 2008). Since then, GF rodents have been extensively used in 
studies concerning the role of gut microbiota in obesity and metabolic disorders. 
GF rodents serve as a simple model to study the effects of individual bacterial 
species on immune functions and metabolism, and indeed, colonization of GF 
rodents with certain gut bacterial species has been shown to cause significant 
changes in the gut barrier function (Wrzosek et al., 2013) and on overall 
metabolism (Bäckhed et al., 2007, Fei & Zhao, 2013).  
As the GF rodents completely lack the normal microbiota and thus possess 
altered immunological functions (Al-Asmakh & Zadjali, 2015), these artificial 
models are not quite optimal for profound studies concerning the role of gut 
microbiota in the onset of metabolic disorders. In addition, intestinal 
monocolonization of single bacterial species is likely to have distorted effects on 
GF mice, because the microbial inter-species networks are completely missing. 
Consequently, several recent studies investigating the role of gut microbes in 
obesity and metabolic disorders have been performed with conventionally bred 
specific-pathogen-free (SPF) rodents that possess diverse gut microbiotas and 
functional immune systems (Brun et al., 2007, Podrini et al., 2013, Jordy et al., 
2015, Xie et al., 2016). In these otherwise metabolically healthy mice, the 
metabolic disturbances are usually induced by HFD-feeding. For example, 
C57BL/6 and ICR mice have been shown to develop obesity and NAFLD in 
response HFD (Podrini et al., 2013, Xin et al., 2014), and as a result, these mice 
are regularly used for studying diet-induced obesity and metabolic disorders. 
Studies on HFD-fed mice have shown that administration of specific bacterial 
strains can modify the metabolic and immunological functions of the host. For 
example, intragastric administration of certain Bifidobacterium or  Lactobacillus 
stains have been demonstrated to reduce liver steatosis in HFD-fed mice (Cano et 
al., 2013, Xin et al., 2014), suggesting that gut microbiota modulation may have 
potential to prevent diet-induced NAFLD. Some studies, however, have reported 
significant inter-individual variation in the susceptibility of the mice to HFD-
induced metabolic disorders, suggesting that like humans, each SPF rodent may 
harbor a unique gut microbiota (Le Roy et al., 2013). This highlights the need for 
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adequate pilot studies and standardization in order to produce high quality 
interventions with minimal within-group variation. 
In addition to dietary models, several animal models that genetically possess 
metabolic disturbances have been generated. One generally approved model is 
ob/ob mouse, which possesses a spontaneous mutation in leptin gene and, in the 
absence of proper leptin-regulated control of satiety, eats excessively (Coleman 
& Hummel, 1973). In comparison to wild type mice, ob/ob mice are extremely 
obese and possess hyperglycemia, IR, and hepatic steatosis (Coleman & 
Hummel, 1973, Takahashi et al., 2012). Another useful model is db/db mouse, 
which has a natural mutation in the leptin receptor gene and consequently 
develops nearly identical metabolic disturbances as the ob/ob mice (Chen et al., 
1996). Both ob/ob and db/db mice are especially used in T2D research, yet their 
phenotype makes them suitable for studying several aspects of the metabolic 
syndrome (Takahashi et al., 2012). 
None of the present animal models completely reflects to the human metabolic 
syndrome or to the hepatic pathophysiology of human NAFLD (Takahashi et al., 
2012, Al-Asmakh & Zadjali, 2015). They have, however, revealed several 
mechanisms that potentially explain the metabolic disturbances associated with 
obesity and metabolic syndrome. For instance, several mouse studies have 
proposed that certain probiotics, i.e. live micro-organisms that have health-
beneficial effects, may ameliorate obesity-related metabolic and immunological 
disturbances of the host (Kang et al., 2010, Cano et al., 2013, Xin et al., 2014, 
Ritze et al., 2014, Alard et al., 2016). These results have had an important role in 
boosting the design of corresponding human interventions investigating the 
possible effects of probiotics on human metabolism. Even though the information 
obtained from mouse studies cannot be directly generalized into humans (Al-
Asmakh & Zadjali, 2015), some randomized controlled trials have successfully 
demonstrated the beneficial effects of certain probiotics also on humans (Alisi et 
al., 2014, Minami et al., 2015). These promising results corroborate that mouse 
models provide a valuable experimental tool for studying the host-microbe 
interactions associated with human diseases and disorders (Al-Asmakh & 
Zadjali, 2015). 
2.4 Targeted gut microbiota modulation 
Changing dietary habits is indisputably the most natural and effective way to 
modify both the gut microbiota composition and the metabolic health of an 
individual (Ravussin et al., 2012, Xiao et al., 2014, Graf et al., 2015, Ussar et al., 
2015). Besides diet, several additional means for gut microbiota modification are 
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available, and constant research is carried out in order to clarify whether these 
approaches could be utilized in improving the metabolic health in a personalized 
manner. 
2.4.1 Probiotics 
Currently, one of the most common ways to modulate the gut microbiota 
composition is the consumption of probiotics and prebiotics. As mentioned 
above, probiotics are live micro-organisms that confer a health benefit on the 
host, whereas prebiotics are non-viable substrates that are selectively utilized by 
micro-organisms that confer beneficial health effects (Hill et al., 2014, Gibson et 
al., 2017). Most pro- and prebiotics are dietary supplements intended to support 
the GI tract homeostasis, and they are widely used for supporting the gut 
microbiota especially during antibiotic courses and dietary changes (Ohland & 
Macnaughton, 2010). The beneficial effects of the products are suggested to 
originate mainly from the enhanced intestinal barrier function that results from 
favorable immunomodulation and competitive colonization (Ohland & 
Macnaughton, 2010). The most commonly used bacterial probiotics belong to 
Bifidobacterium and Lactobacillus genera (Preidis & Versalovic, 2009, Arora et 
al., 2013). In addition, other lactic acid bacteria such as Lactococcus and 
Streptococcus, along with yeast Saccharomyces, are frequently used in probiotic 
supplements (Preidis & Versalovic, 2009, Arora et al., 2013). Additionally, 
genera Bacillus, Enterococcus, Escherichia, and Propionibacterium also include 
certain promising candidates for probiotic applications (Preidis & Versalovic, 
2009). The most studied prebiotics, on the other hand, include polysaccharides 
like inulin and certain fructo-oligosaccharides that enhance the growth of 
Lactobacillae and Bifidobacteria (reviewed in Gérard, 2016). 
Probiotics are suggested to prevent antibiotic-associated diarrhea (Sazawal et al., 
2006, Preidis & Versalovic, 2009), and it is under constant research whether they 
could also ameliorate IBS and IBD (Preidis & Versalovic, 2009, McKenzie et al., 
2016). Recently, both probiotics and prebiotics have also been suggested to 
possess anti-obesity properties (Lee et al., 2007, Kang et al., 2010, Gérard, 2016, 
Borgeraas et al., 2018). Together with reports suggesting that gut microbes can 
contribute to body weight accumulation (Bäckhed et al., 2004, Ley, 2010, Fei & 
Zhao, 2013), these findings indicate that the manipulation of intestinal microbial 
communities could serve as a possible future treatment strategy against obesity 
and metabolic disorders. The studies concerning the effects of probiotics on 
obesity have, however, produced partly controversial results, and the anti-obesity 
effects of probiotics have been demonstrated to be strictly strain-specific. For 
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example, some traditional probiotics like L. acidophilus have been shown to 
rather promote weight gain than to induce weight loss (reviewed in Million et al., 
2012). 
There has lately been increased interest in utilizing certain commensal gut 
microbes as novel probiotic agents in order to improve human health. These new 
probiotic candidates, referred to as next-generation probiotics, include potentially 
health-promoting commensal bacteria such as F. prausnitzii (Martin et al., 2017), 
A. muciniphila (Cani & Van Hul, 2015), and certain species from genera 
Bacteroides and Clostridium (Saarela, 2018). These candidate species possess 
different health-beneficial characteristics, and mouse studies have reported 
promising results regarding their capability to improve host health (Carlsson et 
al., 2013, Cani & Van Hul, 2015, Martin et al., 2015, Schneeberger et al., 2015, 
Martin et al., 2017, Saarela, 2018). Furthermore, the abundances of these bacteria 
have been associated with human health (Miquel et al., 2013, Stenman et al., 
2015, Lopez-Siles et al., 2016). The knowledge on the efficacy and safety of 
these novel probiotic candidates in human consumption is still very limited, and 
comprehensive animal and human trials are needed in order to characterize the 
full probiotic potential of these bacteria (Saarela, 2018). For example, certain 
next-generation probiotic candidates such as B. fragilis are known to possess 
pathogenic potential, and thus careful safety assessments are crucial when 
evaluating the suitability of these bacteria for human consumption (Saarela, 
2018). On the other hand, strain-specific differences in the metabolic capability 
of the commensal gut bacteria are only partially characterized (Martin et al., 
2017), and additionally, various technological challenges must be met before 
strict anaerobes such as. F. prausnitzii can be commercially produced as 
probiotic supplements (Saarela, 2018). Even with these challenges the new 
probiotic candidates hold great promise, and gut microbiota modification by next 
generation probiotics may well provide a future approach for improving human 
metabolic health (Cani & Van Hul, 2015). It must, however, be acknowledged 
that the effects of pre- and probiotics are generally highly individual, and some 
people do not benefit from the products (Reid et al., 2010, Zmora et al., 2018). 
The differences in response to the products are likely to result, at least partly, 
from the differences in the indigenous gut microbiota composition between the 
individuals (Reid et al., 2010, Suez et al., 2018). 
2.4.2 Fecal microbiota transplantation 
Besides pre- and probiotics, other applications for gut microbiota modulation 
also exist. One of these applications is fecal microbiota transplantation (FMT), 
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where feces from a healthy donor in infused to the GI tract of a recipient 
(Cammarota et al., 2017). FMT is already a common practice for treating severe 
recurrent C. difficile diarrhea, and the treatment has been proven to be successful 
for at least approximately 90% of the C. difficile patients (Mattila et al., 2012, 
Kassam et al., 2013). FMT has been reported to induce long-term chances in the 
gut microbiota of the C. difficile patients (Jalanka et al., 2016), suggesting that 
the method could also have potential in treating other microbiota-associated 
diseases such as IBD (Colman & Rubin, 2014). Besides intestinal inflammation, 
the potential of FMT has also been studied in treating obesity and metabolic 
disorders (Gérard, 2016). As already mentioned, metabolic phenotypes have been 
successfully transmitted from conventionally bred mice to GF mice (Turnbaugh 
et al., 2006). In humans, allogenic gut microbiota infusion from lean donors has 
been shown to increase insulin sensitivity in subjects with metabolic syndrome 
(Vrieze et al., 2012). Nevertheless, the reports regarding the effects of donor 
BMI on the weight development of the FMT recipient are scarce and partly 
controversial (Alang & Kelly, 2015, Fischer et al., 2018). Therefore, even if 
FMT may have potential to serve as a possible future method in improving 
obesity and obesity-related metabolic disorders, it is not without concerns, and 
special care should be taken in the screening and selection of the donors. 
Altogether, well-designed clinical trials are required to unveil the full potential of 
FMT on improving the metabolic health of humans. 
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3 AIMS OF THE STUDY 
The aim of this study was to evaluate the role of gut microbes in the emergence 
of metabolic disorders by studying the influence of targeted gut microbiota 
modulation on the metabolic status of the host. 
The specific aims of this study: 
• To set up a high-throughput molecular pipeline for gut microbiota 
composition analysis at the Institute of Biomedicine, University of 
Turku. 
• To characterize the health effects of targeted gut microbiota modification 
by intragastric administration of Faecalibacterium prausnitzii, a 
bacterium previously linked to positive health outcomes. 
• To study the effects of targeted gut microbiota modification by 
intragastric administration of Enterobacter cloacae, a flagella-bearing 
and endotoxin producing bacterium previously linked to obesity and 
metabolic disorders. 
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4 MATERIALS AND METHODS 
4.1 Experimental design of the methodological study (I) 
In this study, five commercial DNA extraction kits were tested and compared in 
order to establish an efficient and practical sample processing protocol to precede 
high-throughput gut microbiota analyses. Fresh stool specimens from four 
healthy Finnish adult donors were derived from a human study approved by the 
Ethics Committee of the Central Finland Health Care District. The performance 
of the DNA extraction kits was evaluated and compared based on ease of use, 
DNA gain, and diversity indices identified by the NGS. In addition, to evaluate 
the influence of the 16S rRNA gene sequencing protocol on the gut microbiota 
composition analysis results, two distinct 16S rRNA gene library preparation 
protocols were applied and the obtained diversity indices and the identified 
phylogenetic composition were compared. Further, the effect of a 21-day sample 
freezer storage (-75°C) on the 16S rRNA gene sequencing results was analyzed 
by comparing the DNA gain, identified bacterial profiles, and the diversity 
indices between the fresh and frozen specimens (unpublished results). Figure 4, 
on the next page, represents the structured scheme of the study. 
4.1.1 DNA extraction from human fecal samples 
Each stool specimen was homogenized by manual mixing and weighted into 
adequate subsamples according to the recommendations of the manufacturers of 
the five DNA extraction protocols. The DNA extractions were performed on the 
day of the sample collection for the fresh specimens and repeated after the 21-
day freezer storage (-75°C). DNA extractions with MagNA Pure 96 DNA and 
Viral NA Large Volume Kit (MP; Roche Diagnostics GmbH, Mannheim, 
Germany) were performed only for the frozen stool specimens. For both fresh 
and frozen specimens, two parallel extractions were performed with each 
protocol. In GXT Stool Extraction Kit VER 2.0 (GXT; Hain Lifescience GmbH, 
Nehren, Germany), cell lysis was enhanced by an additional bead-beating with 
MOBIO PowerLyzer 24 Bench Top Bead-Based Homogenizer (MO BIO 
laboratories, Inc, Carlsbad, CA, USA). Otherwise, all the DNA extractions were 
performed by strictly following the manufacturers’ protocols. The elution volume 
was 200 µl for GXT, QIAamp DNA Stool Mini Kit (QIA; QIAGEN GmbH, 
Hilden, Germany), and QIAamp Fast DNA Stool Mini Kit (QIAF; QIAGEN 
GmbH, Hilden, Germany), and 100 µl for MP and PowerFecal DNA Isolation 
Kit (MOB; MO BIO Laboratories, Inc., Carlsbad, CA, USA). The DNA 
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concentrations were measured with Qubit dsDNA HS assay kit and Qubit 2.0 
fluorometer (Life Technologies, Carlsbad, CA, USA) and the DNAs were stored 
at -75°C. 
 
Figure 4. Workflow of the methodological study (original publication I + unpublished 
results). Abbreviations: QIA = QIAamp DNA Stool Mini Kit (QIAGEN GmbH); QIAF 
= QIAamp Fast DNA Stool Mini Kit (QIAGEN GmbH); MOB = PowerFecal DNA 
Isolation Kit (MO BIO Laboratories, Inc.), GXT = GXT Stool Extraction Kit VER 2.0 
(Hain Lifescience GmbH); MP = MagNA Pure 96 DNA and Viral NA Large Volume 
Kit (Roche Diagnostics GmbH). 
4.1.2 16S rRNA gene sequencing 
Bacterial 16S rRNA gene profiles of the stool specimens were analyzed by two 
distinct Illumina MiSeq 16S rRNA gene sequencing protocols, one detecting the 
V3-V4 hypervariable regions and the other detecting the V4-V5 hypervariable 
regions of the bacterial 16S rRNA gene.  
4.1.2.1 V3-V4 library preparation 
The hypervariable regions V3 and V4 of the bacterial 16S rRNA gene were 
amplified by strictly following the Illumina 16S Metagenomic Sequencing 
Library Preparation Guide (Illumina, 2014). Briefly, the V3-V4 region of the 16S 
rRNA gene was first amplified using gene-specific primers (Klindworth et al., 
2013) that included specific Illumina overhang adapter nucleotide sequences 
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(Table 3; Figure 5). Then, sample-specific multiplexing indices and Illumina 
sequencing adapters were added to the gene-specific sequences in a multiplexing 
PCR step (Illumina, 2014). The expected PCR product size was approximately 
550 bp. 
Table 3. Sequences of the PCR primers used for encoding the 16S rRNA gene 
16S rRNA 
gene region 
Primer sequence (5’ - 3’) 
V3-V4 
forward primer 
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG-
CCTACGGGNGGCWGCAG 
reverse primer 
GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG-
GACTACHVGGGTATCTAATCC 
V4-V5 
forward primer 
AATGATACGGCGACCACCGAGATCTACAC-i5*-
TATGGTAATTGTGTGCCAGCMGCCGCGGTAA 
reverse primer 
CAAGCAGAAGACGGCATACGAGAT-i7*-
AGTCAGTCAGGCCCCGTCAATTCMTTTRAGT 
*i5 and i7 represent the 8-nucleotide index sequences 
 
 
Figure 5. Library preparation protocol for V3-V4 sequencing. First, the 16S rRNA 
gene was amplified with gene-specific primers including specific Illumina overhang 
adapters. Then, in a second PCR, sample-specific indices and Illumina sequencing 
adapters (P5 and P7) were added to the gene-specific sequences. The 16S rRNA 
secondary structure of E. coli has been adapted from XRNA Gallery 
(http://rna.ucsc.edu/rnacenter/xrna/xrna_gallery.html), and the primer binding sites are 
highlighted in grey. The hypervariable regions are highlighted based on (Chakravorty et 
al., 2007). 
46 Materials and methods 
4.1.2.2 V4-V5 library preparation 
Hypervariable regions V4 and V5 of the bacterial 16S rRNA gene were 
amplified in a single PCR (Figure 6) using KAPA HiFi PCR kit (KAPA 
Biosystems, Wilmington, MA, USA) and applying custom-designed indexed 
primers (Table 4) modified from (Kozich et al., 2013). Each PCR reaction 
included 0.3 μM of the primers, 0.3 mM of dNTPs, 0.5 U of polymerase enzyme, 
and 50 ng of DNA template. The PCR program with Veriti® Thermal Cycler 
(Applied Biosystems, Foster City, CA, USA) consisted of an initial denaturation 
at 98°C for 4 min, 25 cycles at 98°C for 20 s, 65°C for 20 s and 72°C for 35 s, 
and a final elongation at 72°C for 10 min. The expected PCR product size was 
approximately 500 bp. 
 
Figure 6. Library preparation protocol for V4-V5 sequencing. The 16S rRNA gene 
was amplified with gene-specific primers including Illumina sequencing adapters (P5 
and P7), sample specific indices (i5 and i7), and specific pad and linker sequences 
(Kozich et al., 2013). The 16S rRNA secondary structure of E. coli has been adapted 
from XRNA Gallery (http://rna.ucsc.edu/rnacenter/xrna/xrna_gallery.html), and the 
primer binding sites are highlighted in grey. The hypervariable regions are highlighted 
based on (Chakravorty et al., 2007). 
4.1.2.3 Illumina MiSeq 16S rRNA gene sequencing 
The PCR products were purified with Agencourt AMPure XP Magnetic beads 
(Beckman Coulter, Inc., Brea, CA, USA) on a DynaMag™-96 magnenic plate 
(Life Technologies), and the PCR products were quality controlled with 
TapeStation (Agilent Technologies, Inc., Santa Clara, CA, USA). The final DNA 
concentrations of the purified 16S rRNA gene libraries were measured with 
Qubit 2.0 fluorometer (Life Technologies, Carlsbad, CA, USA), and the libraries 
were then mixed in equal molar concentrations to generate a library pool with 4 
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nM concentration. The pool was denatured (Illumina, 2014), diluted into 4 pM 
concentration, and spiked with 25% denatured PhiX control (Illumina, Inc., San 
Diego, CA, USA). Paired-end sequencing (2 × 300 bp) was performed with 
Illumina MiSeq system, using MiSeq v3 reagent kit (Illumina, Inc.). 
4.1.3 16S rRNA gene sequence data analysis 
The initial raw sequence quality check was performed with FastQC quality-
control program (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/), 
and data were processed with Qiime (v. 1.9) pipeline (Caporaso et al., 2010, 
Kuczynski et al., 2012, Bokulich et al., 2013). The sequence reads were filtered 
with a quality score acceptance threshold 20, and chimeric sequences were 
filtered using usearch (v. 6.1). Operational taxonomic units (OTUs) were picked 
using uclust algorithm with 97% sequence similarity, excluding OTUs 
representing less than 0.05% of the total sequences. Then, to minimize inter-
sample variation in sequencing efficiency, the OTUs of each sample were 
rarefied to a common sequencing depth by random sampling without 
replacement (Weiss et al., 2017). GreenGenes database (DeSantis et al., 2006) 
was applied for the OTU annotations. 
All analyses of the 16S rRNA gene sequencing data were made from the rarefied 
OTU tables. Taxonomic summary produced by Qiime was visualized as bar 
charts, and statistical differences in the taxonomic richness, i.e. in the OTU 
abundances on taxonomic levels phylum and genus, were assessed with non-
parametric Kruskal-Wallis test. False Discovery Rate (FDR) adjusted p-values < 
0.05 were considered as statistically significant. OTUs existing in less than 25% 
of the samples were excluded prior to statistical testing. 
Statistically significant differences in α-diversity were assessed with Kruskal-
Wallis test from diversity metrics calculated by Qiime. P-values < 0.05 were 
considered as statistically significant. In this thesis, an additional cut-point of p < 
0.01 has been used to emphasize the most distinct findings. Obvious outliers 
were excluded before the analyses. The differences in the overall bacterial 
diversity across the samples were inspected from Principal Coordinate Analysis 
(PCoA) plots produced by Qiime. The PCoA plots were visualized with EMPeror 
(Vázquez-Baeza et al., 2013). To confirm the visual observations, adonis 
analyses (Navas-Molina et al., 2013) were performed. 
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4.2 Experimental design of the mouse studies (II & III) 
Two mouse experiments were performed to study the effects of gut microbiota 
modification on the emergence of metabolic disorders. The basic study design of 
the experiments was similar (Figure 7). In both experiments, two control groups, 
one on high-fat diet (HFD) and the other on chow diet, were given sterile 
phosphate buffered saline (PBS) intragastrically twice a week, every other week. 
At the same time, a bacterial treatment group on HFD was intragastrically 
administered with approximately 2 × 108 live bacterial cells dissolved in PBS 
twice a week, every other week. Both experiments lasted for 13 weeks, after 
which the mice were sacrificed and their whole blood, gut content, gut tissue, 
adipose tissue, and liver were collected. The animal experiments were approved 
by the National Animal Experiment Board in Finland (license: 
ESAVI/7258/04.10.07/2014), and all animal work was performed in accordance 
with the guidelines of the Act on the Use of Animals for Experimental Purposes 
by the Ministry of Agriculture and Forestry, Finland. 
 
Figure 7. Simplified schematic presentation of the mouse studies (original 
publications II and III). Two control groups, one receiving HFD and the other receiving 
chow diet, were intragastrically given PBS twice a week, every other week. The 
bacterial treatment group received approximately 2 × 108 live bacterial cells, either F. 
prausnitzii or E. cloacae, twice a week, every other week. The experiments lasted for 13 
weeks, after which the mice were sacrificed and their tissues were collected. 
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4.2.1 Mice 
7-week-old C57BL/6N female mice were purchased from Charles River 
laboratories (Germany) via Scanbur. At the age of 8 weeks, the mice were 
randomly divided into HFD control, chow control and bacterial treatment groups 
(n = 6 per group). Baseline stool samples were collected into Nunc® CryoTubes 
(Sigma-Aldrich, Saint Louis, MI, USA), immersed into liquid nitrogen, and 
stored at -80°C. During the 13-week experiments, the mice were housed in 
individually ventilated cages under SPF conditions, three mice per cage. The 
mice received food and water ad libitum and were maintained on a 12/12-hour 
light/dark cycle. Upon arrival, all mice received irradiated chow diet (58124 DIO 
Rodent Purified Diet w/10% energy from fat) purchased from Labdiet/Testdiet, 
UK. When the experiment started, the HFD control group and the bacterial 
treatment groups were switched to chow-matching HFD (58126 DIO Rodent 
Purified Diet w/60% energy from fat), while the chow control group continued 
on the chow diet throughout the experiment (Table 4). Food intake in each cage 
was monitored at four or five different time points during the experiment, by 
weighing the consumed food per cage in 24-hour periods. Food intake per mice 
was then estimated by dividing the food consumption of the cage by the number 
of mice living in the cage. Body weight of the mice was measured weekly, 
always at the same time of the day. One mouse from the HFD control group and 
one from the E. cloacae treatment group were excluded from the study, as they 
suffered from significant weight loss during the treatment period. 
Table 4. Composition of the diets 
 
 
 
 
 
 Chow dieta High-fat dietb 
Ingredient % % kcal % % kcal 
Protein 16.9 18.0 23.1 18.1 
Carbohydrates 67.4 71.8 25.9 20.3 
Fat 4.3 10.2 34.9 61.6 
Fiber 4.7  6.5  
kcal/g (kJ/g) 3.76 (15.7)  5.10 (21.3)  
aTestDiet® DIO Rodent Purified Diet w/10 % Energy from Fat 
bTestDiet® DIO Rodent Purified Diet w/60 % Energy from Fat 
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4.2.2 Bacterial cultures and intragastric bacterial administration 
F. prausnitzii ATCC® 27766™ pure cultures were maintained at +37°C on yeast 
extract, casitone, fatty acid, and glucose (YCFAG) agar plates (modified from 
(Lopez-Siles et al., 2012) in Whitley A35 anaerobic workstation (Don Whitley 
Scientific, UK). Intragastric inoculums were prepared by suspending the cultured 
bacterial cells in sterile PBS at a turbidity-based estimated cell density of 9 × 108 
CFU/ml. The volume of each portion, including approximately 2 × 108 bacterial 
cells, was 220 µl. The suspensions were prepared at anaerobic atmosphere using 
anaerobic PBS, and the dosing syringes were sealed with Parafilm® M to enable 
the viability of the bacteria prior to the administration. At the time of transferring 
the suspension into the dosing syringe, the viability of the suspended bacterial 
cells was confirmed by plating an aliquot of the suspension on YCFAG agar 
plate. The sealed syringes were then transported to the animal facility, and the 
bacterial suspensions were administered to the mice intragastrically. 
E. cloacae subspecies cloacae ATCC® 13047™ pure cultures were maintained 
at +37°C on Fastidious anaerobe blood agar plates (Lab M Limited, Lancashire, 
UK). Intragastric inoculums were prepared similarly as the F. prausnitzii 
inoculums, by suspending the bacterial cells in sterile PBS at an approximate cell 
density of 9 × 108 CFU/ml. The volume of each inoculum was 220 µl, including 
approximately 2 × 108 bacterial cells. At the time of transferring the bacterial 
suspension into the dosing syringe, the viability of the bacteria was confirmed by 
plating an aliquot of the suspension on Fastidious anaerobe blood agar plate. The 
dosing syringes were sealed with Parafilm® M and transported to the animal 
facility, and the suspensions were administered to the mice intragastrically. 
4.2.3 Tissue sample collection 
After the 13-week treatment period, the overnight-fasted mice were euthanized 
by CO2 exposure, and their whole blood was drawn by cardiac puncture. 
Euthanasia was confirmed by cervical dislocation. Whole blood samples, 
collected by the cardiac puncture, were transferred into serum tubes, and after 
adequate clotting of approximately 30 minutes, the samples were centrifuged at 
10 000 × g for 5 minutes to separate serum from cells. The serums were then 
divided into several Eppendorf tubes and stored at -80°C. 
All tissues were collected with sterile instruments. Separate instruments were 
used for each tissue type, and the instruments were disinfected in ethanol 
between each dissection. The subcutaneous adipose tissue (SAT) and visceral 
adipose tissue (VAT) were harvested and weighed with an electronic scale. 
 Materials and methods 51 
Approximately 3 mm pieces of the adipose tissues were fixed in 10x w/v Tris-
buffered zinc fixative (2.8 mM calcium acetate, 22.8 mM zinc acetate, 36.7 mM 
Zinc chloride in 0.1 M Tris-buffer, pH 7.4) for 24 hours at RT. The fixed tissues 
were washed with H2O and PBS, 1 hour at RT with each, and then stored in PBS 
at +4°C until embedded in paraffin. Rest of the adipose tissues were placed in 
Nunc® CryoTubes (Sigma-Aldrich, Saint Louis, MI, USA), snap frozen by 
immerging in liquid nitrogen and stored at -80°C. These tissue samples were later 
pulverized in liquid nitrogen, using mortar and pestle, to obtain homogenous 
mixtures of the whole tissues for protein and gene expression analyses. 
The liver tissue was harvested and weighed with electronic scale. Part of the right 
lobe of the liver was cut and embedded in Tissue-Tek® O.T.C. compound 
(Sakura® Finetek Europe, Leiden, Netherlands) and snap frozen in liquid 
nitrogen for immunohistochemical analyses. Rest of the liver was placed in 
Nunc® CryoTube, submerged in liquid nitrogen and stored at -80°C. For fat 
content analysis, along with protein and gene expression analyses, the tissue 
samples were later pulverized in liquid nitrogen. Left and right gastrocnemius 
muscle tissues were dissected, weighted with electronic scale and placed in 
Nunc® CryoTubes that were immediately submerged in liquid nitrogen and then 
stored at -80°C. For the protein and gene expression analyses, the tissue samples 
were later pulverized in liquid nitrogen. Last, the whole intestine was dissected, 
and the colon and cecum contents were collected into Nunc® CryoTubes, 
submerged immediately into liquid nitrogen and stored at -80°C. The intestinal 
tissue was weighed with electronic scale, transferred into Nunc® CryoTube, snap 
frozen in liquid nitrogen and stored at -80°C. Subsequently, the tissue samples 
were pulverized in liquid nitrogen for gene expression analyses. 
4.2.4 Tissue sample analyses 
4.2.4.1 Analyses of the serum samples 
Serum glucose, glycerol, aspartate transaminase (AST), and alanine transaminase 
(ALT) were analyzed at the clinical laboratory of the Department of Sport and 
Health Sciences, University of Jyväskylä, using KONELAB 20XTi analyzer 
(Thermo Fischer Scientific, Vantaa, Finland) and standard KONELAB reagents 
(Thermo Fischer Scientific, Vantaa, Finland). 
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4.2.4.2 Liver triacylglycerol measurements and AST and ALT analyses 
Total lipids from the liver tissues were extracted by a method modified from 
(Folch et al., 1957). Approximately 30 mg of the pulverized tissue was 
homogenized in 2:1 (v/v) chloroform/methanol (CHCl3:MeOH) and washed with 
0.9 % KCl. Phases were separated by centrifugation at 2000 × g for 3 min. The 
lower organic phase was saved, and for the upper phase, 86:14 (v/v) 
CHCl3:MeOH was added and the extraction was repeated. Then the upper phase 
was discarded, and both organic phases were combined and evaporated to 
dryness under nitrogen stream. The dried lipid extract was dissolved in ethanol, 
and the TAG content was determined with KONELAB 20XTi analyzer. In study 
II, a more comprehensive additional fraction isolation method was used in order 
to enable fatty acid methyl ester analyses by gas chromatography (method 
described in original publication II). 
To analyze AST and ALT levels directly from liver, approximately 20 mg of 
pulverized liver tissue was transferred into ice-cold lysis buffer (10 mM Tris-
HCl, 150 mM NaCl2, 2 mM EDTA, 1% Triton X-100, 10% glycerol and 1 mM 
DTT) supplemented with protease and phosphatase inhibitors (Sigma Aldrich, St 
Louis, USA) and homogenized with TissueLyser (Qiagen, Valencia, CA, USA). 
After centrifugation at 12 000 x g for 10 min, AST and ALT were measured from 
the soluble liver protein extract with KONELAB 20XTi analyzer (Thermo 
Fischer Scientific, Waltham, MA, USA). 
4.2.4.3 Gene expression analyses 
Total RNA was extracted from the pulverized tissues using TissueLyser (Qiagen, 
Hilden, Germany) and Trizol reagent (Invitrogen, Carlsbad, CA, USA), by 
following the manufacturer’s protocol. The RNA concentrations were measured 
with NanoDrop™ 2000 spectrophotometer (Thermo Fisher Scientific, Waltham, 
MA, USA), and the RNAs were then stored at -80°C. For gene expression 
analyses, RNA was reversely transcribed using High Capacity cDNA Synthesis 
Kit (Applied Biosystems, Foster City, CA, USA), by following the 
manufacturer’s instructions. Real-time quantitative PCR (qPCR) analyses were 
performed according to the MIQE quidelines (Bustin et al., 2009), using either 
in-house designed primers (purchased from Invitrogen) or primers derived from 
Mouse Primer Depot (http://mouseprimerdepot.nci.nih.gov/), iQ SYBR 
Supermix, and CFX96™ Real-time PCR Detection System (Bio-Rad 
Laboratories, Richmond, CA, USA). The target genes and the sequences of all 
qPCR primers used in the mouse studies are presented in Table 5. The PCR 
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program consisted of an initial denaturation at 95°C for 10 min, followed by 40 
cycles at 95°C for 10 s, 60°C for 30 s, and +72°C for 30 s, and finally 5 s at 
+65°C. The relative expression values were calculated against a standard curve 
with the CFX96™ Software and normalized to the expression level of either 
ACTB mRNA or PicoGreen-quantified dsDNA (Quant-iT PicoGreen dsDNA 
Assay Kit, Invitrogen; Lundby et al., 2005). Each sample was analyzed in 
duplicate. 
Table 5. Sequences of the qPCR primers used in this study 
Target 
gene 
Forward primer (5’ - 3’) Reverse primer (5’ - 3’) 
Original 
publication 
Acc2 GAGGCTGCATTGAACACAAG TGTTCTCGGCCTCTCTTCAC II + III 
Actb GGCTGTATTCCCCTCCATCG CCAGTTGGTAACAATGCCATGT II + III 
Adipoq CCTGGAGAGAAGGGAGAGAAA CGAATGGGTACATTGGGAAC II + III 
Adipor GGAGTGTTCGTGGGCTTAGG GCAGCTCCGGTGATATAGAGG II + III 
Ccl2 AGGTGTCCCAAAGAAGCTGTA ATGTCTGGACCCATTCCTTCT III 
Cdkn1a CGGTGTCAGAGTCTAGGGGA AGGATTGGACATGGTGCCTG II 
Cs GCCATGGCTCTACTCACTGC ATTCGTGGAAGAAGCACTGG II 
Ddit4 GCCTCTGGGATCGTTTCTCG GGTCAAGGCCCTCTTCTCTG II 
Dgat2 CGCAGCGAAAACAAGAATAA GAAGATGTCTTGGAGGGCTG II + III 
Il1b TGTGAAATGCCACCTTTTGA GGTCAAAGGTTTGGAAGCAG III 
Insr CAGCCGGATGGGCCAATGGGA CTCGTCCGGCACGTACACAGAA II + III 
Mgll AAAGTTTGTCGGAGAATCGG AAAGTTTGTCGGAGAATCGG III 
Mmp9 AGACGACATAGACGGCATCC CTGTCGGCTGTGGTTCAGT III 
Rela TTTCGATTCCGCTATGTGTG GAACGATAACCTTTGCAGGC III 
Tjp1 GAGCGGGCTACCTTACTGAAC GAGCGGGCTACCTTACTGAAC II + III 
Tlr4 
CAAGAACATAGATCTGAGCTTC
AACCCGCT 
GTCCAATAGGGAAGCTTTCTAGAG III 
Tlr5 AAGTTCCGGGGAATCTGTTT GCATAGCCTGAGCCTGTTTC II + III 
Xbp1 TGCTGAGTCCGCAGCAGGTG TGCTGAGTCCGCAGCAGGTG III 
4.2.4.4 Protein expression analyses 
Proteins from the pulverized tissues were extracted at 4°C with TissueLyser 
(Qiagen, Hilden, Germany), using ice-cold lysis buffer (10 mM Tris-HCl, 150 
mM NaCl2, 2 mM EDTA, 1% Triton X-100, 10% glycerol and 1 mM DTT) 
supplemented with protease and phosphatase inhibitors (Sigma-Aldrich, Saint 
Louis, MI, USA). The protein concentrations were measured with Pierce BCA 
Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA). 
Approximately 20 to 40 µg of the protein extracts were separated by SDS-Page 
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using 4-20 % Criterion precast gradient gels (Bio-Rad Laboratories, Inc., 
Hercules, CA, USA) and transferred to nitrocellulose membranes. The 
membranes were visualized with Ponceau S staining and blocked with Odyssey 
Blocking Buffer (Li-COR Biosciences, Lincoln, NE, USA) for 1 hour at RT. The 
Western blot analyses were performed using primary antibodies against phospho-
Acc (Ser79) phospho-Akt (Ser473), phospho-AS160 (Thr642), phospho-HSL 
(Ser660) (Cell Signaling Technology, Danvers, MA, USA), PGC1α (Abcam, 
Cambridge, UK), and Total OXPHOS Rodent WB Antibody Cocktail that 
includes antibodies against ATP5A, MTCO1, NDUFB8, SDHB, and UQCRC2 
(Abcam, Cambridge, UK). Odyssey anti-rabbit IRDye 800 or anti-mouse IRDye 
680 (LI-COR Biosciences, Lincoln, NE, USA) were used as secondary 
antibodies, and the blots were scanned and quantified with Odyssey CLX 
Infrared Imager (Li-COR Biosciences, Lincoln, NE, USA). If re-probing was 
necessary, the membranes were incubated for 10 min in 0.2 M NaOH at RT, 
washed with TBS and re-probed with appropriate antibodies. All samples and 
results were normalized to two Ponceau S stained bands due to differences in 
housekeeping GAPDH expression levels between the groups. 
4.2.4.5 Histological and immunohistochemical analyses 
For morphological analysis of the liver, 5 µm sections from the frozen liver 
tissues were cut with Leica CM3000 Cryostat (Leica, Wetzlar, Germany) at -
24°C and stained with Hematoxylin & Eosin (H&E) using standard protocols. To 
evaluate the degree of liver steatosis (Levene et al., 2012), the sections were 
stained with Oil Red O as previously described (Weston et al., 2015). In addition, 
acetone-fixed liver sections were stained with Cy3-conjugated anti-smooth 
muscle actin (SMA; Sigma-Aldrich, Saint Louis, MO, USA). Imaging was done 
using an inverted wide-field microscope (Carl Zeiss, Oberkochen, Germany) 
with a confocal unit and 40× oil/1.4 NA objective (Carl Zeiss). 
Paraffin-embedded adipose tissues were cut into 5 µm sections and stained 
immunohistochemically using Vectastain Elite ABC kit (Vector Laboratories, 
Burlingame, CA, USA) to determine whether leukocytes had translocated into 
the adipose tissues. Staining was performed by following the manufacturer’s 
instructions, using anti-mouse CD45 (clone 30F-11; BD Biosciences, Franklin 
Lakes, NJ, USA) as a primary antibody. Diaminobenzidine (Dako, Agilent 
Technologies, Santa Clara, CA, USA) was used as a chromogen, and 
counterstaining was done using Mayer’s hematoxylin. The number of CD45 
positive cells was calculated manually from the stained sections. On average, 
cells from approximately 10 fields of view were calculated, and the results were 
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presented as the number of cells per field. In addition, the adipocyte sizes from at 
least 500 randomly selected cells in each sample group were determined with 
CellProfiler 2.2.0. 
4.2.4.6 DNA extraction from stool and colon samples 
The DNA from approximately 100 mg frozen baseline stool samples and from 
post-treatment colon content samples were extracted with GTX Stool Extraction 
Kit VER 2.0 and GenoXtract® instrument (Hain Lifescience, Nehren, Germany) 
combined with an additional bead-beating in 0.1 mm Glass Bead Tubes (MO 
BIO Laboratories, Inc.) with MO BIO PowerLyzer™ 24 Bench Top Bead-Based 
Homogenizer (MO BIO Laboratories, Inc.) at 1000 rpm for 3 minutes. DNA 
concentrations of the extracts were measured with Qubit dsDNA HS assay kit 
and Qubit 2.0 fluorometer (Life Technologies, Carlsbad, CA, USA). The DNAs 
were stored at -75°C until the 16S rRNA gene library preparation and sequencing 
(described in chapter 4.1.2.2). 
4.2.5 Statistical analyses 
Statistical analyses of the mouse studies were performed with either IBM SPSS 
Statistics 22 (IBM, Armonk, NY, USA) or JMP Pro 12 (SAS Institute, Inc., Cary, 
NC, USA). All data were checked for normality using Shapiro-Wilk´s test. For 
body weight, one-way ANOVA and Tukey’s range test were used to analyze the 
differences between the study groups. The group differences in gene expression 
and protein phosphorylation levels, liver TAG content, and in the numbers of 
leukocytes were analyzed with non-parametric Kruskal-Wallis test and Mann 
Whitney U test, as the data were not normally distributed. P-values < 0.05 were 
considered as statistically significant. In this thesis, an additional cut-point p < 
0.01 has been used to emphasize the most distinct findings. 
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5 RESULTS 
5.1 Effects of sample storage, DNA extraction, and sequencing 
protocol on the 16S rRNA gene sequencing results (I) 
All evaluated commercial DNA extraction kits performed sufficiently in 
extracting DNA from human stool specimens for NGS analysis. The DNA gain 
(µg per gram of feces) was, however, significantly higher with GXT than with 
any other method in both fresh and frozen specimens (Steel-Dwass All Pairs p < 
0.01 for all). In addition, for frozen specimens, extraction with QIA resulted in a 
significantly higher DNA gain than the extractions with MOB or QIAF (p < 0.01 
for both). 
5.1.1 DNA extraction method had relatively little impact on the 16S rRNA 
gene sequencing results 
The observed bacterial diversity of the fecal samples, represented as average 
Shannon indices, was not dependent on the DNA extraction protocol (p = 0.91 
for fresh samples [unpublished data] and p = 0.89 for frozen samples). Inter-
individual differences, by contrast, were explicit (Kruskal-Wallis p < 0.01). In 
principal coordinate analysis (PCoA) plot, as well as in Jack-Knifed Unweighted 
Pair Group Method with Arithmetic Mean (UPGMA) Tree, the subsamples of 
each original specimen clustered together, irrespective of the DNA extraction 
method (Original publication I, Figures 4 and 5). Furthermore, adonis analysis 
reported no differences between the DNA extraction methods (p = 1.0), whereas 
grouping by study subjects was statistically significant (p < 0.01). 
When only the frozen samples were assessed (original publication I), the phylum 
level bacterial composition of the samples, i.e. the OTU abundances, was not 
dependent on the DNA extraction method. In V4-V5 sequencing, samples 
extracted with MP tended to have slightly higher Firmicutes-to-Bacteroidetes 
ratios compared to the samples extracted with other methods (p = 0.08), but this 
tendency was not observed in the V3-V4 sequencing (p = 0.2). No other phylum 
level differences were observed between the DNA extraction methods in neither 
V3-V4 nor V4-V5 sequencing. In the bacterial genus level, on the other hand, the 
abundances of genera Coprococcus and Dorea appeared to significantly vary 
between samples extracted with distinct protocols (FDR < 0.05 for both). This 
was observed in both V3-V4 and V4-V5 sequencing. However, the overall 
abundance of both these genera was extremely low. 
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When fresh and frozen samples were analyzed together (unpublished data), 
Qiime reported statistically significant differences in V4-V5 sequencing for 
phyla Actinobacteria and Proteobacteria (FDR < 0.05 for both); the abundance 
of Actinobacteria was highest in the samples extracted with GXT or MP, while 
the abundance of Proteobacteria was highest in the samples extracted with 
QIAF. With V3-V4 sequencing, no differences in the phylum level bacterial 
composition were observed between the extraction protocols. Further, no DNA 
extraction -dependent differences in the Firmicutes-to-Bacteroidetes ratio were 
observed with neither V3-V4 nor V4-V5 sequencing when the fresh and frozen 
samples were analyzed together. By contrast, several genus level differences 
were observed between the DNA extraction methods: along with Coprococcus 
and Dorea, the abundance of Blautia, Ruminococcus, Dialister, and Odoribacter 
varied significantly with both V3-V4 and V4-V5 sequencing (FDR < 0.05 for 
all). Further, in V4-V5 sequencing, the abundance of genus Faecalibacterium 
differed between the extraction protocols (FDR < 0.05), while in V3-V4 
sequencing, the abundance of genus Oscillospira varied significantly between the 
extraction protocols (FDR < 0.05). 
5.1.2 Freezer storage tended to affect the Firmicutes-to-Bacteroidetes ratio of 
the fecal samples 
The 21-day freezer storage had a divergent effect on the DNA gain (µg per g of 
feces) between the different extraction methods (unpublished data). With QIA, 
the DNA gain was significantly higher after the freezer storage (Mann-Whitney 
U test p = 0.04), whereas with MOB and QIAF, the DNA gain was significantly 
lower after the freezer storage (p < 0.01 for both). With GXT, no significant 
differences in the DNA gain were observed between the fresh and frozen 
specimens (p = 0.25). MP extractions were performed only for the frozen 
specimens, and thus no comparisons could be made. The MP results were, 
however, included in the analyses comparing the fresh and frozen specimens, 
because based on the results of original publication I, this was expected to have 
little impact on the results. 
The observed α-diversity of the samples, represented as average Shannon indices, 
was not affected by the freezer storage (p = 0.42; unpublished data). 
Nevertheless, especially in V4-V5 sequencing, the freezer storage tended to 
affect the bacterial profiles produced by the 16S rRNA gene sequencing: In V4-
V5 sequencing, the abundance of phylum Firmicutes was significantly higher in 
the frozen specimens (FDR < 0.05), whereas Bacteroidetes abundance tended to 
be higher in the fresh specimens (FDR = 0.054). Accordingly, the Firmicutes-to-
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Bacteroidetes ratio tended to be lower in the freshly isolated specimens (p = 
0.06). Further, genus level differences between the fresh and frozen fecal 
samples were seen in the abundances of Dorea, Bifidobacterium and 
Faecalibacterium; the abundances of all these genera were significantly higher in 
the frozen specimens (FDR < 0.05 for all; unpublished data). In V3-V4 
sequencing, on the other hand, no statistically significant differences were 
observed in the abundance of any bacterial phyla or genera between the fresh and 
frozen specimens, but again, the Firmicutes-to-Bacteroidetes ratio tended to be 
lower in the freshly extracted samples (p = 0.09). Further, when the V3-V4 and 
V4-V5 sequencing results were analyzed together, the shift in the Firmicutes-to-
Bacteroidetes ratio appeared statistically significant (p < 0.05). However, when 
the samples extracted with MP were excluded from the analysis, the difference 
became statistically insignificant (p = 0.16).  
5.1.3 16S rRNA gene sequencing results were highly dependent on the 16S 
rRNA gene library preparation protocol 
The sequencing results produced with the two distinct 16S rRNA gene library 
preparation protocols differed significantly from each other (original publication 
I). The average OTU counts of the samples were significantly higher with V4-V5 
sequencing (Mann-Whitney U test p < 0.01), whereas the average Shannon 
indices were significantly higher with V3-V4 sequencing (p < 0.01). The samples 
analyzed with the different protocols clustered separately in the PCoA plot 
(Original publication I, Figure 7), and Jack-Knifed UPGMA tree revealed two 
distinct clusters. Adonis analysis affirmed that a remarkable portion of variation 
between the samples could be attributed to the 16S rRNA gene sequencing 
protocol (p < 0.01). 
When observing the taxonomic bacterial composition of the samples, the 
abundances of phyla Actinobacteria, Bacteroidetes, Proteobacteria, and 
Firmicutes differed significantly between the V3-V4 and V4-V5 sequencing 
(FDR < 0.05 for all); the average Bacteroidetes abundance was higher with V4-
V5 sequencing, whereas the abundances of the other phyla were higher with V3-
V4 sequencing. In addition, the Firmicutes-to-Bacteroidetes ratio was 
significantly higher in V3-V4 sequencing (p < 0.01). Further, in the bacterial 
genus level, several statistically significant differences were observed between 
the V3-V4 and the V4-V5 sequencing protocols (original publication I). The 
results concerning the taxonomic bacterial profiles remained basically unaltered 
when the freshly-isolated and frozen samples were analyzed together 
(unpublished data). 
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5.2 Effects of intragastric F. prausnitzii administration on mouse 
metabolism and liver fat accumulation (II) 
No statistically significant differences in long-term food intake were observed 
between the study groups, even though the food consumption of the HFD 
controls seemed to be slightly elevated compared to the chow controls and the F. 
prausnitzii -treated mice. At the endpoint of the study, no statistically significant 
differences in serum glycerol or glucose concentrations were observed between 
the study groups. 
5.2.1 F. prausnitzii treatment reduced hepatic fat accumulation 
The mice treated with F. prausnitzii had reduced liver TAG levels compared to 
the HFD controls (p < 0.05; Table 6), and their hepatic fat content, visualized by 
Oil Red O staining, was significantly lower. In addition, less lipid ballooning and 
liver fibrosis were observed in the F. prausnitzii -treated mice and the chow 
controls compared to the HFD controls (Original publication II, Figure 1). Based 
on gas chromatography analysis, the molar percentages of hepatic lipid classes 
18:0 (stearate), 20:4n-6 (arachidonic acid), 20:5n-3 (eicosapentaenoic acid), and 
22:6n-3 (docosahexanoic acid) in TAGs were significantly reduced in the F. 
prausnitzii -treated mice compared to the HFD controls. In chow controls, 
majority of the lipid classes in TAGs were reduced compared to the HFD 
controls. Furthermore, the percentages of several fatty acids in phospholipids 
were decreased in both the F. prausnitzii -treated mice and the chow controls 
compared to the HFD controls. The F. prausnitzii -treated mice and the chow 
controls expressed more TAG-synthesizing diacylglycerol-acyltransferase 
(Dgat2) and fatty-acid synthesizing acetyl coenzyme carboxylase (Acc2) mRNA 
than the HFD controls (p < 0.05 for all), but compared to the HFD controls, the 
F. prausnitzii -treated mice also expressed more lipid metabolism -enhancing 
adiponectin receptor (Adipor; p < 0.01). Chow controls did not increase Adipor 
expression but instead significantly increased the insulin receptor (Insr) 
expression (p < 0.01). Furthermore, the F. prausnitzii -treated mice had 
significantly lower hepatic AST and ALT values compared to the HFD controls 
(p < 0.05 for both) and more Ser79-phosphorylated Acc (p < 0.05). 
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Table 6. Effects of the F. prausnitzii treatment on the physiology and 
tissue-specific gene/protein expression of the HFD-fed C57BL/6N mice 
Tissue Effects of the F. prausnitzii treatment* 
Liver  Triacylglycerol (TAG) levels 
 Lipid ballooning 
 Diacylglycerol-acyltransferase (Dgat2) expression 
 Acetyl coenzyme carboxylase (Acc2) expression 
 Adiponectin receptor (Adipor) expression 
 Acc phosphorylation 
 Hepatic AST and ALT levels 
Subcutaneous 
adipose tissue (SAT) 
 SAT mass 
 Number of CD45+ cells 
 AS160 phosphorylation 
Visceral adipose 
tissue (VAT) 
 Number of CD45+ cells 
 VAT-specific adiponectin (Adipoq) expression 
 Insulin receptor (Insr) expression 
 Hormone sensitive lipase (HSL) phosphorylation 
Muscle  Gastrocnemius muscle mass 
 ATP5A, UQCRC2, and MTCO1 expression 
Gut  Tight junction protein-encoding gene (Tjp1) expression 
 Firmicutes abundance 
 Bacteroidetes abundance 
*Statistically significant differences between the F. prausnitzii -treated mice and the 
HFD controls are presented.  = increase;  = decrease. 
5.2.2 F. prausnitzii treatment reduced adipose tissue inflammation and 
appeared to increase insulin sensitivity in VAT 
The F. prausnitzii -treated mice had significantly higher SAT mass than the chow 
controls (p < 0.01) and the HFD controls (p < 0.05; Table 6). The number of 
CD45-positive cells in the SAT of the F. prausnitzii -treated mice was, however, 
significantly lower than in the HFD controls (p < 0.05), and the phosphorylation 
of AS160 was increased in comparison with the control groups (p < 0.05 for 
both). 
The differences in VAT mass were not significant between the F. prausnitzii -
treated mice and the HFD controls (Original publication II, Figure 3), but the 
number of CD45-positive cells in the VAT of F. prausnitzii treatment group was 
significantly lower (p < 0.01). Further, in comparison to the HFD control mice, 
the adipocytes of the F. prausnitzii -treated mice appeared smaller, and they 
expressed more visceral fat specific adipokine, adiponectin (Adipoq; p < 0.05). In 
addition, the VAT of the F. prausnitzii -treated mice expressed more Insr (p < 
0.05) than the HFD controls, while the insulin-responsive hormone sensitive 
lipase (HSL)-ser660 phosphorylation was elevated (p < 0.05). The F. prausnitzii 
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treatment did not, however, affect the expression of cytokine interleukin-1 beta, 
Il1b (unpublished data). 
5.2.3 F. prausnitzii treatment increased gastrocnemius muscle size and 
modified the gut microbiota composition 
F. prausnitzii -treated mice had significantly higher gastrocnemius muscle mass 
than the control mice (compared to the HFD controls, p < 0.05 for the left 
gastrocnemius and p < 0.01 for the right gastrocnemius; Table 6). In addition, the 
F. prausnitzii -treated mice expressed more mitochondrial ATP5A, UQCRC2, 
and MTCO1 (p ≤ 0.05 for all) compared to the HFD controls. No differences in 
the expression levels of peroxisome proliferator -activated receptor coactivator 
1α (PGC1α), NDUFB8, and SDHB, or in the phosphorylation levels of Acc, 
AS160, or HSL, were observed (data not shown). 
While the pre-treatment mouse fecal samples had similar phylum level bacterial 
profiles, the post-treatment samples differed between the study groups. Most 
prominently, the F. prausnitzii treatment seemed to increase the Firmicutes-to-
Bacteroidetes ratio of the gut microbiota (Original publication II, Figure 6A); the 
F. prausnitzii -treated mice had significantly less Bacteroidetes and more 
Firmicutes than the HFD control mice (p < 0.05 for both), and a similar trend 
was also seen between the F. prausnitzii treatment group and the chow controls 
(p = 0.07 for both). At the genus level, the F. prausnitzii -treated mice had, for 
example, more Lactobacillus and Streptococcus bacteria than the control groups 
(p < 0.05 for both). In addition, compared to the HFD controls, the F. prausnitzii 
-treated mice expressed more intestinal tight junction protein-encoding Tjp1 
mRNA (p < 0.05). 
5.3 Effects of intragastric E. cloacae administration on mouse 
metabolism and liver fat accumulation (III) 
No differences were observed in the weight gain of the HFD-fed study groups 
during the E. cloacae experiment (Original publication III, Figure 1A). By 
contrast, in the second and third week of the study, the E. cloacae -treated mice 
weighted significantly more than the chow controls (p < 0.05 for both), while at 
the endpoint of the experiment, both the E. cloacae -treated mice and the HFD 
controls weighted significantly more than the chow controls (p < 0.01 and p < 
0.05, respectively). 
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5.3.1 E. cloacae treatment increased serum AST values but not hepatic 
steatosis 
The E. cloacae -treated mice had significantly higher serum AST values 
compared to the chow controls (p < 0.01) and the HFD controls (p < 0.05; Table 
7). TAG-synthesizing Dgat2 expression was increased in the E. cloacae -treated 
mice compared to the HFD controls (p < 0.05), but the liver TAG content did not 
significantly differ between the study groups. The expression of fat metabolism -
enhancing Adipor was, however, increased in the E. cloacae -treated mice 
compared to the control groups (p < 0.05 for both). On the other hand, E. cloacae 
-treated mice had decreased AS160 phosphorylation levels compared to the 
control mice (p < 0.05 for both; Original publication III, Figure 5). The H&E 
staining revealed significantly less lipid ballooning in the chow controls 
compared to the HFD controls and the E. cloacae -treated mice, and in SMA 
staining, E. cloacae -treatment group seemed to express more SMA than the 
control groups (Original publication III, Figure 6). 
Table 7. Effects of E. cloacae treatment on the physiology and tissue-
specific gene/protein expression of the HFD-fed C57BL/6N mice 
Tissue Effects of the E. cloacae treatment* 
Serum 
 Serum AST 
 Serum glycerol 
Liver 
 Diacylglycerol-acyltransferase (Dgat2) expression 
 Adiponectin receptor (Adipor) expression 
 AS160 phosphorylation 
Subcutaneous adipose 
tissue (SAT) 
 Fat mass 
 Insulin receptor (Insr) expression 
 Mgll expression 
 Proportion of hypertrophic adipocytes 
 Number of CD45+ cells 
 X-box binding protein 1 (Xbp1) expression 
Visceral adipose tissue 
(VAT) 
 VAT-specific adiponectin (Adipoq) expression 
 Insulin receptor (Insr) expression 
 NF-κβ p65 mRNA (NFκB) expression 
 Akt phosphorylation 
*Statistically significant differences between the E. cloacae -treated mice and the 
HFD controls are presented.  = increase;  = decrease. 
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5.3.2 E. cloacae treatment activated lipolysis, but also increased adiponectin 
expression in VAT 
Compared to the chow controls, the E. cloacae -treated mice and the HFD 
controls had significantly increased VAT masses (p < 0.05 for both). The 
expression of hepatic fat oxidation -enhancing VAT-specific adipokine, Adipoq, 
was significantly higher in the E. cloacae -treated mice compared to the HFD 
controls (p < 0.05; Table 7). Compared to the HFD controls, the E. cloacae -
treated mice and the chow controls had higher expression levels of NF-κβ p65 
mRNA (NFκB; p < 0.05 and p < 0.01, respectively). In addition, the E. cloacae -
treated mice and the chow controls expressed more Insr than the HFD controls (p 
< 0.05 and p < 0.01, respectively). On the other hand, the VAT of the E. cloacae 
-treated mice had lower phosphorylation levels of Akt-ser473 than the VAT of the 
control mice (p < 0.05 for both), and the phosphorylation of HSL-ser660 was 
decreased in comparison to the chow controls (p < 0.05). In addition, compared 
to the chow controls, the monoacylglycerol lipase (Mgll) expression in the VAT 
of the E. cloacae -treated mice was significantly elevated (p < 0.01).  
5.3.3 E. cloacae treatment increased fat mass and the percentage of 
hypertrophic adipocytes in SAT 
The SAT mass of E. cloacae -treated mice was elevated compared to the HFD 
and chow controls (p < 0.05 for both; Table 7). In addition, the expression level 
of Insr in the SAT of E. cloacae -treated mice was significantly lower than in the 
control groups (p < 0.01 for both). The SAT of the chow controls had 
significantly more phosphorylated Acc than the HFD controls (p < 0.05) and the 
E. cloacae treatment group (p < 0.01). In addition, the HSL-ser660 
phosphorylation was higher in the chow controls than in the HFD controls (p < 
0.01) and the E. cloacae -treated mice (p < 0.05). On the other hand, the Mgll 
expression was significantly higher in the E. cloacae -treated mice than in the 
HFD controls (p < 0.05) and chow controls (p < 0.01), and in accordance, the E. 
cloacae treatment group had significantly higher serum glycerol levels than the 
control mice (p < 0.05 for both). Based on H&E staining and cell size counting, 
the E cloacae treatment group had a higher proportion of hypertrophic (30-40 
µM) adipocytes than the HFD control mice (p < 0.01). Nevertheless, the E. 
cloacae -treated mice had less endoplasmic reticulum (ER) stress -related spliced 
X-box binding protein 1 (Xbp1) than the HFD controls (p < 0.05) and 
significantly less CD45-positive cells in the SAT than the control groups (p < 
0.01 for both). 
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6 DISCUSSION 
6.1 16S rRNA gene sequencing results are highly dependent on the 
sample pre-processing protocols and the applied analysis methods 
During the past decade, the methodological development in the NGS protocols 
has revolutionized the gut microbiota research. Ever since the high-throughput 
analysis protocols have become more cost-effective, they have also become more 
readily available, and consequently, the number of studies concerning the role of 
gut microbiota on human health has escalated (Tringe & Hugenholtz, 2008, 
Hamady & Knight, 2009). Along with large consortiums and population-wide 
study projects, e.g. The Human Microbiome Project (Turnbaugh et al., 2007), 
Metagenomics of the Human Intestinal Tract (Ehrlich & MetaHIT Consortium, 
2011), and The American Gut Project (McDonald et al., 2015), a vast number of 
independent laboratories and study groups are performing high quality gut 
microbiota research. Consequently, the knowledge on the structure and functions 
of the gut microbes is continuously expanding. However, despite the constant 
development in the analysis protocols, standardization and comparability of the 
gut microbiota NGS studies remains a challenge (Cardona et al., 2012, Kennedy 
et al., 2014, Santiago et al., 2014, IHMS, 2015, Costea et al., 2017). Therefore, 
aiming at enhancing the data quality and result comparability, we analyzed the 
impact of different 16S rRNA gene targeting primers and different sample 
preprocessing methods, i.e. sample freezing and different DNA extraction 
methods, on the results of the NGS-based gut microbiota composition analysis. 
The results of this study reveal that the 16S rRNA gene sequencing protocol has 
a significant impact on the gut microbiota composition analysis results. 
Furthermore, our results show that the sample pre-processing protocols, i.e. 
freezer storage and DNA extraction, also affect the analysis results, but compared 
to the effect of the 16S rRNA gene library preparation protocol, the overall 
effects of the pre-processing appear relatively minor. 
In this study, five different DNA extraction protocols, two storage conditions 
(fresh vs. frozen samples) and two 16S rRNA gene sequencing protocols (V3-V4 
sequencing vs. V4-V5 sequencing) were evaluated in order to develop a well-
working pipeline for gut microbiota composition analysis. As reported previously 
(Liu et al., 2008, Klindworth et al., 2013, Starke et al., 2014, Tremblay et al., 
2015) and reaffirmed in this study, the selected 16S rRNA gene sequencing 
protocol has a major impact on the microbial community analysis results. In this 
study, both the observed bacterial diversities and the taxonomic profiles of the 
samples were highly dependent on the 16S rRNA gene sequencing protocol. 
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However, as both the 16S rRNA gene target region and the library preparation 
PCR protocol varied between the evaluated methods, it cannot be concluded 
whether the differences in the results occurred due to the gene target region or 
due to the differences in the PCR methodology. For example, in addition to the 
differences in the PCR protocols and chemistries, the ability of the applied 
primers to bind to the DNA of different bacterial species may have varied. 
Additionally, the V3-V4 sequencing and the V4-V5 sequencing were performed 
in different laboratories, which may have had a substantial effect on the results. 
Nevertheless, our findings underline the importance of careful evaluation of the 
16S rRNA gene library preparation protocols. The storage conditions prior to the 
DNA extraction, on the other hand, mainly appeared to affect the Firmicutes-to-
Bacteroidetes ratio of the samples. Even though the difference in the ratio was 
not statistically significant when samples extracted with MP were excluded from 
the analysis, our results suggest that freezer storage prior to the DNA extraction 
may slightly decrease the relative abundance of phylum Bacteroidetes in the 
fecal samples. The same phenomenon has been reported previously in a 
quantitative PCR based study (Bahl et al., 2012). The Firmicutes-to-
Bacteroidetes ratio is a frequently used biomarker related to human physiology 
(Ley et al., 2006, Armougom & Raoult, 2008, Ley, 2010), but due to partially 
inconsistent results in some studies (Duncan et al., 2008, Collado et al., 2008, 
Schwiertz et al., 2010, Raman et al., 2013), the validity of the ratio remains 
controversial. Our findings suggest that the incompatibility between the studies 
may at least partly arise from differences in the sample pre-processing. At the 
same time, our V4-V5 sequencing results also indicate that the sample storage 
conditions may cause variation in the bacterial genus level composition. Of the 
observed differences, especially the higher relative abundance of F. prausnitzii in 
the frozen specimens may have importance, as F. prausnitzii is considered as a 
possible biomarker for a healthy human gut (Lopez-Siles et al., 2017, Martin et 
al., 2017). Thus, overall, the results of this study emphasize that standardization 
of the sample collection and storage is crucial in the gut microbiota composition 
studies, and that all samples analyzed together should be processed with identical 
methods. In addition, our results underline that comparisons of studies conducted 
with different analysis methods are not reliable. 
Of the five DNA extraction methods evaluated in this study, QIAamp DNA Stool 
Mini Kit (QIAGEN GmbH, Hilden, Germany) is one of the two DNA extraction 
methods recommended by the International Human Microbiome Standards 
(IHMS, 2015). It is a manual extractions protocol based on chemical cell lysis 
and DNA capture by silica membranes. QIAamp Fast DNA Stool Mini Kit 
(QIAGEN GmbH, Hilden, Germany) is a simplified version of QIAamp DNA 
Stool Mini Kit, yet still an entirely manual DNA extraction kit. This protocol also 
is based on chemical cell lysis and DNA capture by silica membranes. 
66 Discussion  
PowerFecal DNA Isolation Kit (MO BIO Laboratories, Inc., Carlsbad, CA, 
USA), on the other hand, is a manual DNA extraction kit relying on bead-beating 
cell lysis and DNA capture by silica membranes. GXT Stool Extraction Kit VER 
2.0 for GenoXtract® instrument (Hain LifeScience GmbH, Nehren, Germany) is 
a semi-automatic DNA extraction kit based on magnetic bead technology, while 
MagNA Pure 96 DNA and Viral NA Large Volume Kit (Roche Diagnostics 
GmbH, Mannheim, Germany) relies on chemical cell lysis and magnetic bead 
technology. Even though MagNA Pure is a high-throughput DNA extraction 
instrument, the extraction protocol includes several manual pre-processing steps 
and is thus considered to be semi-automatic in this study. To our knowledge, this 
was the first study to evaluate the usability of these semi-automatic DNA 
extraction methods in 16S rRNA gene sequencing -based gut microbiota 
composition analysis. Overall, there were no significant variation in the 
efficiency of the tested DNA isolation protocols; all kits performed sufficiently in 
extracting DNA from the fecal samples (see Chapter 5.1.1). However, when 
considering the amount of labor affiliated with each extraction protocol, the 
semi-automated methods clearly rose above the manual methods. This suggest 
that the semi-automatic methods offer a practical option to substitute the manual 
extraction kits in the sample pre-processing. This could significantly enhance the 
sample processing time and decrease the hands-on time in the NGS studies. In 
addition, even though not observed in this study, semi-automatic methods are 
likely to provide improved reproducibility compared to manual methods, as 
manual methods are more prone to human errors for example in pipetting. Use of 
automation could therefore possibly stabilize the quality of the DNA extractions 
and, to some extent, subsequently increase the comparability of 16S rRNA gene 
sequencing results between different laboratories. 
The effect of DNA extraction on the results of microbial profile and diversity 
analyses has been extensively investigated in several previous studies (Salonen et 
al., 2010, Maukonen et al., 2012, Kennedy et al., 2014, Wesolowska-Andersen et 
al., 2014, Cruaud et al., 2014, Starke et al., 2014, Wagner Mackenzie et al., 2015, 
Costea et al., 2017), but due to partially conflicting results, no clear consensus on 
the matter has been reached. The inconsistences may have arisen from overall 
methodological differences, since in addition to evaluating different DNA 
extraction kits, variable sample collection and storage procedures have been used 
in the studies. Furthermore, the analysis methods have been variable. And on the 
other hand, it has been reported that even if two extraction protocols produce 
similar results for one sample, they may result in contradictory results for another 
(Cruaud et al., 2014), which suggests that the effects of the DNA extraction may 
be sample-dependent. Thus, the results of this study may not be fully comparable 
with any previous studies, as fecal samples from only four adult donors were 
analyzed. However, overall, the results of this study, along with previous studies 
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(Salonen et al., 2010, Wagner Mackenzie et al., 2015), indicate that inter-
individual variation of the fecal samples clearly exceeds the variation resulting 
from the choice of the DNA extraction protocol. Altogether, our results suggest 
that all DNA extraction kits evaluated in this study are suitable to precede the 
16S rRNA gene sequencing when studying inter-individual differences of the GI 
tract microbiota profiles. Yet, to enhance the validity of the results, the obtained 
methods should always be adequately optimized. Further, the results of this study 
are not applicable to other downstream protocols. For example, significant DNA 
extraction dependent differences have been reported in the results of shotgun 
metagenome sequencing (Costea et al., 2017). 
6.2 F. prausnitzii has the potential to restrain liver fat accumulation, 
whereas E. cloacae may be able to cause liver damage 
The underlying mechanisms in the pathogenesis of NAFLD and NASH are still 
incompletely understood. Currently, the most prevailing theory is that the 
induction and progression of hepatic steatosis and liver inflammation require 
multiple parallel factors to act together (reviewed in Buzzetti et al., 2016). These 
factors presumably include, for instance, genetic factors (Kantartzis et al., 2009), 
increased gut permeability (Miele et al., 2009), and adipose tissue dysfunction 
and inflammation (Tilg & Hotamisligil, 2006, Buzzetti et al., 2016). In addition, 
one important factor is IR, which in the liver promotes hepatic de novo 
lipogenesis and in the adipose tissue increases lipolysis that consequently 
increases the efflux of FFAs into the liver (Buzzetti et al., 2016, Bril et al., 2017). 
These factors seem to act both consecutively and simultaneously, and together 
predispose the liver to steatosis and lipotoxicity (Lomonaco et al., 2012, Bril et 
al., 2017). This lipotoxicity is suggested to induce oxidative stress and further 
impairment in the insulin signaling, as well as activation of several inflammatory 
cascades (Cusi, 2010, Lomonaco et al., 2012). The so-called multiple-hit 
hypothesis may explain why all obese individuals do not develop metabolic 
syndrome or NAFLD. In addition, it may explain why the progression of 
NAFLD varies highly between individuals, encompassing a wide spectrum of 
conditions from mild steatosis to severe NASH (Buzzetti et al., 2016). 
Because gut microbes play a crucial role in regulating the intestinal permeability, 
bacterial-based treatment has been suggested to serve as a possible future method 
to treat or prevent NAFLD and other metabolic disorders (Cano et al., 2013, 
Lambert et al., 2015). In this study, we aimed at exploring the effects of 
intragastric bacterial treatment on host health and metabolism in C57BL/6N 
mice. The intragastric bacterial treatment was performed with either F. 
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prausnitzii (original publication II) or E. cloacae (original publication III). These 
intestinal bacterial species were selected, because several previous studies had 
reported F. prausnitzii to obtain health-promoting properties (Sokol et al., 2008, 
Miquel et al., 2014, Rossi et al., 2016), whereas E. cloacae had been associated 
with obesity and IR (Fei & Zhao, 2013). Further, a previous study by our 
research group had reported that human subjects with NAFLD possessed 
significantly decreased F. prausnitzii abundances and meanwhile tended to have 
slightly increased enterobacteria abundances in their fecal samples (Munukka et 
al., 2014). The effects of either F. prausnitzii or E. cloacae treatment were 
studied by comparing the bacterial-treated HFD-fed C57BL/6N mice to HFD 
control mice that served as models of NAFLD, and to chow control mice that 
served as healthy controls. Even though the chow controls acted as healthy 
controls, the comparison of the bacterial-treated mice and the HFD controls 
tended to be more informative in this study, because the effects of the bacterial 
treatments could not be comprehensively distinguished from the effects of the 
HFD. 
The fat mass of the mice was elevated in both the F. prausnitzii as well as the E. 
cloacae treatment groups, which is a natural consequence of the HFD in 
C57BL/6 mice (Jo et al., 2009). As no bacterial treatment group fed with chow 
diet was included in the studies, it remains uncertain whether the fat mass of the 
mice would have also increased as a consequence of the intragastric bacterial 
administration e.g. due to excessive SCFA production (Bäckhed et al., 2004), or 
whether it was solely due to the HFD. Therefore, no firm conclusions about the 
role of the bacterial administration on the overall fat mass accumulation can be 
drawn in this study. However, the results of this study suggest that the effects of 
the F. prausnitzii treatment and the E. cloacae treatment on mouse metabolism 
were indisputably different. For example, the influence of the F. prausnitzii 
treatment on insulin signaling resembled the effects of the chow diet, suggesting 
that the F. prausnitzii treatment could avert the harmful effects of the HFD, 
whereas the results of the E. cloacae -treated mice rather indicated adipose tissue 
IR. In addition, based on the H&E staining and cell size counting, the E. cloacae 
treatment group had more hypertrophic (30-40 µM) adipocytes than the HFD 
controls. Hypertrophy, i.e. increased adipocyte size, together with hyperplasia, 
i.e. increased adipocyte number, are normal mechanisms for adipose tissue 
expansion (Rutkowski et al., 2015), but excess hypertrophy can lead to adipocyte 
hypoxia that is suggested to have an important role in the development of adipose 
tissue inflammation and IR (Olefsky & Glass, 2010, Sun et al., 2011). However, 
while the adipose tissue inflammation and IR are usually associated with ER 
stress and infiltration of leukocytes into the adipose tissue (Olefsky & Glass, 
2010), both bacterial treatment groups had significantly less CD45-positive cells 
in their SAT in comparison to the control groups. In addition, the E. cloacae -
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treated mice had less ER stress -related spliced Xbp1 than the HFD controls. The 
expression of Xbp1 was not studied in the F. prausnitzii experiment. The 
underlying reasons for these findings could not be identified. 
6.2.1 Mechanisms by which F. prausnitzii treatment may enhance host health 
and metabolism 
In this study, we observed that the F. prausnitzii (ATCC® 27766™) treatment 
decreased the hepatic fat content of the HFD fed mice; the hepatic fat content of 
the F. prausnitzii -treated mice was significantly low compared to the livers of 
the HFD controls. In addition, the F. prausnitzii -treated mice had significantly 
lower hepatic AST and ALT values than the HFD controls. In general, our 
findings regarding the hepatic lipid measurements, histological liver samples, and 
the AST and ALT values support each other and together suggest that the F. 
prausnitzii -treated mice had healthier livers than the HFD controls. Overall, our 
results thus indicate that F. prausnitzii had a capability to advert the negative 
effects of HFD and consequently restrain NAFLD in the HFD-fed mice. 
Although the underlying mechanisms could not be fully elucidated in this study, 
certain effects of the bacterial treatment on the metabolic activities of the host 
were identified that could have contributed to the prevention of the liver fat 
accumulation. For instance, in the VAT, the expression of insulin receptor (Insr), 
as well as the insulin-stimulated HSL-ser660 phosphorylation, were significantly 
higher in the F. prausnitzii -treated mice and the chow controls in comparison to 
the HFD controls, which indicates that the VAT of the HFD controls may have 
been less insulin sensitive. Further, while obesity often is associated with adipose 
tissue inflammation and an infiltration of leukocytes, especially macrophages, 
into the adipose tissues, the number of CD45 positive cells in the adipose tissues 
of the F. prausnitzii -treated mice was decreased compared to the HFD controls, 
even though the fat mass was high in both groups. This suggests that the adipose 
tissues of the F. prausnitzii -treated mice may have been less inflamed. As 
previously mentioned, adipose tissue IR and inflammation not only affect the 
adipose tissue itself but play important roles in the overall metabolism. Adipose 
tissue IR, for instance, tends to increase TAG lipolysis, which subsequently leads 
to excess supply of the FFAs into the liver and thus predisposes the liver to 
excess hepatic fat accumulation (Lomonaco et al., 2012, Bril et al., 2017). 
Meanwhile, adipose tissue inflammation is considered as one of the key factors 
contributing to the pathogenesis of NAFLD, because in addition to further 
promoting the IR (Olefsky & Glass, 2010), it alters the secretion of adipokines 
and pro-inflammatory cytokines that can have systemic effects (Tilg & 
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Hotamisligil, 2006). As mesenteric VAT drains to hepatic portal system, liver 
may be especially exposed to cytokines secreted by this tissue (Rytka et al., 
2011, Item & Konrad, 2012). Furthermore, significantly high adiponectin 
expression was observed in the VAT of the F. prausnitzii –treated mice in 
comparison to the HFD control mice. Adiponectin has been reported to obtain 
insulin-sensitizing effects on whole organism level, and low concentrations of 
this adipokine have been previously associated with obesity and related 
metabolic disorders (Liu et al., 2012, Caselli, 2014). Therefore, our results 
suggest that the F. prausnitzii treatment may have been able to block some of the 
adipose tissue related factors that, based on the multiple hit hypothesis (Buzzetti 
et al., 2016), play central roles in the development of NAFLD. 
In addition to the suppression in adipose tissue IR and inflammation, the reduced 
liver fat accumulation of the F. prausnitzii -treated mice may be explained by 
enhanced hepatic fatty-acid oxidation and lipid clearance. Compared to the HFD 
controls, the F. prausnitzii -treated mice had high expression values of hepatic 
Adipor, which has previously been suggested to improve IR, enhance fat 
metabolism, and possess anti-inflammatory activities (Tilg & Hotamisligil, 
2006). In addition, the F. prausnitzii -treated mice, as well as the chow controls, 
had significantly high hepatic Acc phosphorylation levels in comparison to the 
HFD controls, which possibly indicates reduced lipogenesis and enhanced fatty 
acid oxidation (Ha et al., 1994, Fullerton et al., 2013). Thus, the suppressed 
hepatic fat accumulation in the F. prausnitzii -treated mice in comparison to the 
HFD controls may have been due to enhanced hepatic fatty-acid metabolism. In 
general, the effects of the F. prausnitzii treatment on the liver of the mice largely 
resembled the effects of the chow diet. The chow controls, however, did not 
significantly increase the hepatic Adipor expression in comparison to the HFD 
controls, but instead significantly increased the hepatic insulin receptor (Insr) 
expression. This suggests that the liver metabolism of the chow controls differed 
from the F. prausnitzii -treated mice, which is not surprising, as the F. prausnitzii 
-treated mice had to process the excess fat in their diet. Retrospectively, it would 
have been extremely enlightening to also study a bacterial treatment group fed 
with chow diet. 
One of the mechanisms through which F. prausnitzii possibly affected the health 
of the mice was its ability to favorably modulate the gut integrity by increasing 
Tjp1 expression. This was quite expected, as F. prausnitzii is an important 
producer of butyrate, which has already previously been associated with 
increased gut epithelial integrity and alleviated intestinal inflammation 
(Chapman et al., 1994, Hamer et al., 2009). In fact, several studies have already 
reported that F. prausnitzii may be capable of improving the gut epithelial health 
(Benus et al., 2010, Carlsson et al., 2013, Martin et al., 2014). In addition, other 
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anti-inflammatory bacteria have been previously reported to support intestinal 
barrier function and the gut integrity (Eun et al., 2011, Bomhof et al., 2014), 
suggesting that certain bacterial species or bacterial fermentation products may 
be crucial for maintaining the intestinal health. However, based on the 16S rRNA 
gene sequencing, F. prausnitzii was not able to permanently inhabit the gut of the 
mice in this study. This was possibly either due to insufficient amount of 
inoculated bacterial cells or too few inoculations during the experiment. 
Alternatively, the GI tract of the mice may have not offered a favorable habitat 
for the bacterium, or the HFD may have prevented the long-term colonization. 
Yet even in these circumstances, the F. prausnitzii treatment was able to cause 
evident health effects and to modify the overall gut microbiota composition. This 
suggests that even a short-term colonization of the bacterium, possibly due to the 
anti-inflammatory compounds produced by it, is sufficient to induce beneficial 
effects on the host health. Interestingly, the F. prausnitzii treatment also 
increased the mouse muscle mass, which seemed to be linked to enhanced 
mitochondrial respiration. This finding supports the previous suggestion that gut 
microbes could affect the muscle size and metabolism (Bindels & Delzenne, 
2013). Nevertheless, a bit surprisingly, we did not observe any differences in the 
expression of protein PGC1α, which is one of the main regulators of oxidative 
metabolism and has been previously related to muscle growth (Puigserver & 
Spiegelman, 2003, Bäckhed et al., 2007). Yet, as only the endpoint situation was 
studied, it is possible that the F. prausnitzii -treated mice had higher PGC1α 
expression levels at some earlier point during the experiment.  
Taken together, the results of this study suggest that the intragastric F. prausnitzii 
treatment was able to advert the negative effects of HFD and protected the mice 
from NAFLD. Furthermore, our results suggest that the F. prausnitzii -treated 
mice were metabolically healthier than the HFD controls. Our findings are in line 
with several previous studies that have reported associations between F. 
prausnitzii supernatant and metabolic and immunological health of mice 
(Carlsson et al., 2013, Huang et al., 2016, Rossi et al., 2016, Wang et al., 2017). 
To our knowledge, this was the first study to show that intragastric F. prausnitzii 
administration could prevent liver fat accumulation in mice. 
6.2.2 Possible mechanisms behind the harmful effects of E. cloacae treatment 
The results of this study demonstrate that, contrary to the F. prausnitzii 
treatment, E. cloacae subsp. cloacae (ATCC® 113047™) administration induced 
adipose tissue hypertrophy and hepatic damage in the HFD-fed mice. Altogether, 
the E. cloacae treatment tended to have negative effects on the mouse 
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metabolism. For example, even though the E. cloacae treatment did not have a 
significant effect on the liver fat content in comparison to the HFD control mice, 
the treatment significantly elevated the serum AST values of the mice. 
Additionally, the E. cloacae treatment group seemed to express more SMA than 
the control groups, which along with the high serum AST values indicates liver 
damage. Thus, in conclusion, our results suggest that E. cloacae treatment was 
able to cause liver damage in the HFD-fed mice. Enterobacteria have already 
previously been associated with liver function; the abundance of phylum 
Proteobacteria, including the Enterobacteriaceae family, is suggested to be 
increased in NAFLD and NASH patients (Zhu et al., 2013, Shen et al., 2017) and 
increased enterobacteria abundances have also been reported in patients with 
liver cirrhosis (Chen et al., 2011). Furthermore, in accordance with our results, 
previous studies have reported that E. cloacae strain B29, a close relative to E. 
cloacae ATCC® 113047™, is able to induce obesity and liver injure in HFD fed 
GF mice (Fei & Zhao, 2013, Yan et al., 2016). 
The mechanisms underlying the harmful effects of the E. cloacae treatment 
appeared unforeseeably complicated and thus remained largely unresolved in this 
study. For example, the reduced Insr expression in SAT, along with increased 
serum glycerol levels and increased Mgll expression in both SAT and VAT, 
indicate that the E. cloacae treatment may have caused partial insulin resistance 
that subsequently increased adipose tissue lipolysis, but this could not be 
confirmed in this study. Impaired regulation of lipolysis can cause adipocyte 
hypertrophy, which again is suggested to contribute to ER stress, adipose tissue 
inflammation, and further exacerbation of the adipose tissue IR (Olefsky & 
Glass, 2010, Sun et al., 2011, Makki et al., 2013, Morigny et al., 2016). 
However, as already mentioned, the E. cloacae treatment group had significantly 
less CD45-positive cells in their SAT in comparison to the control groups, and 
less ER stress -related spliced Xbp1 than the HFD controls. Furthermore, since 
no insulin tolerance tests were performed, it cannot be confirmed that insulin 
resistance existed.  
There were no differences in the insulin-stimulated HSL-ser660 phosphorylation, 
which inhibits the action of HSL, between the E. cloacae -treated mice and the 
HFD controls in neither SAT, VAT, or liver. Compared to the chow controls, on 
the other hand, both HFD fed groups had significantly low phosphorylation 
levels in each tissue. HSL is known to induce lipolysis, and it has been suggested 
to contribute to IR and NAFLD by releasing glycerol into the portal vein (Karpe 
et al., 2011). Meanwhile, the E. cloacae -treated mice, along with the chow 
controls, had significantly higher hepatic TAG-synthetizing Dgat2 expression in 
comparison to the HFD controls, but the liver TAG content did not significantly 
differ between the study groups. This may at least partly arise from the increased 
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expression of the fat metabolism -enhancing Adipor in the E. cloacae -treated 
mice in comparison to the control mice, but the underlying reason for the 
elevated adipokine receptor expression remains unknown. In addition, the Adipoq 
expression in the VAT of the E. cloacae -treated mice was elevated – this finding 
is contrary to the previous results obtained with E. cloacae strain B29 (Fei & 
Zhao, 2013). On the other hand, compared to the control mice, the E. cloacae -
treated mice had decreased AS160 phosphorylation levels, which potentially 
decreased the glucose incorporation into glycogen in liver (Hargett et al., 2016). 
It remains to be determined whether the contradictory results stem from strain-
specific differences or some methodological reason such as inadequately frequent 
bacterial administrations. As the gut microbiota composition was not analyzed in 
this study, it is not definite that the colonization of the bacterium was successful, 
and furthermore, the effects of the E. cloacae treatment on the overall gut 
microbiota composition remain unknown. Further, it remains uncertain whether 
the E. cloacae administration alone would have been adequate to cause the 
effects observed in this study, or whether synergy with the HFD was required. In 
GF mice, E. cloacae and HFD have been suggested to possess a synergistic effect 
that contributes to obesity and metabolic disorders (Fei & Zhao, 2013, Yan et al., 
2016). Thus, it is possible that also in conventionally bred mice E. cloacae is able 
to predispose the host to metabolic dysfunction and liver damage only when the 
intestinal barrier function is already hampered due to the HFD. This should be 
confirmed in future studies. Altogether, the results of this study indicate that the 
intragastric administration of certain bacterial species, in this case E. cloacae, is 
adequate to possess harmful effects on mouse metabolism, at least when 
combined with HFD. 
6.3 F. prausnitzii as a possible future probiotic 
The results of this study strengthen the supposition that F. prausnitzii has health-
beneficial potential, and further suggest that the therapeutic use of this bacterium 
should be further studied. For example, humans having low abundance of F. 
prausnitzii in their GI tract could benefit from the targeted gut microbiota 
modulation. While previous studies have already reported that certain 
Lactobacillus strains are able to prevent NAFLD in mice (Ritze et al., 2014, Xin 
et al., 2014), to our knowledge, this was the first study to suggest that NAFLD 
could be reduced by intragastric delivery of live F. prausnitzii cells. However, 
due to an extremely small sample population in this study, further interventions 
are needed in order to confirm our findings. Moreover, as the results from mouse 
studies are not straightforwardly applicable in human population, well-designed 
randomized controlled trials are required in order to comprehensively elucidate 
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the effects of F. prausnitzii on human metabolism. So far, an obvious challenge 
hampering the research on F. prausnitzii, as well as its possible therapeutic use, 
has been the extremely oxygen sensitive nature of the bacterium that has made it 
difficult to culture and preserve (Duncan et al., 2002, Martin et al., 2017). 
Strategies to increase the vitality of F. prausnitzii upon exposure to air are under 
constant development (Khan et al., 2014), possibly simplifying the culture 
conditions and making the production of probiotic supplements less challenging 
in the future. On the other hand, another potential approach to reveal the 
therapeutic impact of F. prausnitzii in human metabolism could be the 
identification and production of prebiotic dietary supplements that promote the 
growth of F. prausnitzii in the human GI tract. And in addition to the probiotic or 
prebiotic treatments, FMT has recently been proposed as one possible therapeutic 
method to improve obesity and associated metabolic disorders in humans (Vrieze 
et al., 2012, Gérard, 2016). As F. prausnitzii is one of the most abundant 
bacterial species in a healthy human gut (Suau et al., 2001, Miquel et al., 2014, 
Ferreira-Halder et al., 2017), it may have an important role in the overall effects 
of FMT. Research on this approach is still scarce, and method standardization 
and extensive randomized controlled trials are required in order to unveil the true 
capability of FMT to improve human metabolic health (Gérard, 2016). 
Propitiously, several ongoing randomized clinical trials have already been listed 
in the database of privately and publicly funded clinical studies 
(https://www.clinicaltrials.gov). 
6.4 Limitations of the study 
A small sample size is indisputably the main limitation in all subprojects of this 
study. Fecal samples from only four adult donors were analyzed in the 
methodological sub-study, and due to that no firm conclusions can be drawn 
from the acquired results. Further, the group sizes in the mouse studies were 
limited to 6 mice per study group, which hampered certain statistical analyses 
and may have thus affected the results and conclusions. In addition, the results 
from the mouse studies obviously cannot be generalized into human population. 
Although mice are a valuable study model, human and mice differ in both gut 
microbiota composition and overall metabolism (Takahashi et al., 2012). And as 
already discussed above, the analysis methods for gut microbiota composition 
analysis are developing extremely fast, and the 16S rRNA gene sequencing is 
already often supplemented or replaced by more powerful methodologies like 
shotgun metagenome sequencing. For this reason, certain findings of this study 
can already be considered as slightly outdated. In addition, it is a well-known fact 
that the 16S rRNA gene sequencing, like any molecular method, is prone to 
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biases (Kennedy et al., 2014, Santiago et al., 2014, Wagner Mackenzie et al., 
2015), which may have affected the microbiota results of the original 
publications I and II. In future studies examining the role of gut microbiota 
modulation on host health, shotgun metagenome sequencing could provide a 
more profound picture on the composition and gene content of the microbes, 
whereas metatranscriptomics, metaproteomics and metabolomics could be 
applied to assess information about the functional changes in the gut. 
In the mouse sub-studies, on the other hand, some drawbacks occurred that 
should be taken into account when planning the forthcoming rodent studies. For 
example, the HFD was so soft that even with chewing toys the teeth of the mice 
tended to overgrow, which affected the eating habits of the mice and potentially 
caused variation. In addition, there were certain misfortunes in the sample 
collection of the E. cloacae sub-study, and for instance 16S rRNA gene 
sequencing could not be included in the study because flaws in markings 
disallowed reliable identification of the sample tubes. Additionally, in future gut 
microbiota modification studies, the required amount of the inoculated bacteria, 
as well as an adequate administration schedule, should be more comprehensively 
determined in order to confirm a steady and constant colonization of the bacteria. 
And notably, bacterial treatment groups fed with chow diet should be included in 
the future studies in order to assess the effects of the bacterial treatment without 
synergetic effects with the HFD. For instance, in the F. prausnitzii study, it 
would have been interesting to see whether the fat mass of the mice would have 
also increased as a consequence of the intragastric bacterial administration, or 
whether it was solely due to the HFD. Further, in the E. cloacae study, it would 
have been important to assess whether the E. cloacae administration alone would 
have caused the liver damage observed in this study, or whether a heathier diet 
would have been adequate to protect the host from the harmful effects of the 
bacterial administration. 
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7 CONCLUSIONS 
The methodological subproject of this study concludes that semi-automatic DNA 
extraction methods are practical and well-working options for the sample pre-
processing in NGS studies. In addition, this study, along with previous studies 
(Bahl et al., 2012, Klindworth et al., 2013, Santiago et al., 2014, Kennedy et al., 
2014, Brooks et al., 2015, Karst et al., 2018), highlights that comprehensive 
optimization of both pre-processing and analysis methods is required in order to 
produce reliable 16S rRNA gene sequencing results. 
 
Figure 8: Summary of the main findings of studies II and III. As previously shown 
(Podrini et al., 2013), high-fat diet (HFD) induces hepatic fat accumulation in 
C57BL/6N mice. Gut microbiota modulation by intragastric F. prausnitzii 
administration seems to avert the detrimental effects of the HFD, whereas gut 
microbiota modulation by intragastric E. cloacae administration appears to induce liver 
damage. The effects of the HFD are presented as differences between the HFD controls 
and the chow controls, whereas the effects of the bacterial treatments are presented as 
differences between the bacterial treatment groups and the HFD controls.  = increase; 
 = decrease. 
The results of the mouse studies suggest that F. prausnitzii treatment protects 
from the HFD-induced NAFLD in an experimental mouse model, whereas E. 
cloacae treatment causes liver damage (Figure 8). The underlying preventive 
mechanisms of the F. prausnitzii treatment likely involve increased fatty-acid 
oxidation and adiponectin signaling in liver and increased adiponectin expression 
in VAT. In addition, the F. prausnitzii -treatment seems to decrease the 
inflammation and increase the insulin sensitivity in the adipose tissues. By 
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contrast, the E. cloacae treatment tends to increase lipolysis and IR in the mouse 
adipose tissues, along with increasing SAT mass and the relative proportion of 
hypertrophic adipocytes. 
In general, the findings of this study underline that the therapeutic potential of F. 
prausnitzii should be further studied. For example, humans with low abundance 
of F. prausnitzii could benefit from targeted gut microbiota modification. On the 
other hand, the results of this study emphasize the previously reported harmful 
effects of E. cloacae. In this study, the E. cloacae treatment caused liver damage 
without affecting the hepatic TAG content. Even though the results regarding the 
hepatic fat metabolism were partially contradictory to previous reports (Fei & 
Zhao, 2013), this study agrees with the previously demonstrated hypothesis that 
an increased proportion of E. cloacae in the GI tract may be harmful to the host 
health. The gained knowledge from this study can be utilized in the development 
of animal models in which the effects of the gut microbiota on host health and 
metabolism can be further assessed. One interesting future study goal could be to 
assess whether the onset of metabolic disorders and NAFLD in humans could be 
prevented by increasing the GI tract F. prausnitzii abundance or by strengthening 
the overall gut homeostasis via FMT. As long as the clinical applications of F. 
prausnitzii are hampered by its obligate anaerobic nature, another possible study 
goal could be to assess prebiotic dietary supplements that promote the growth of 
the bacterium. In fact, certain dietary supplements that promote the growth of F. 
prausnitzii have already been identified (Ramirez-Farias et al., 2008). 
Meanwhile, discovery of anti-inflammatory molecules secreted by F. prausnitzii 
may provide a step towards novel therapeutic applications. Research on this field 
is still in its infancy, but certain promising molecules have already been 
identified (Quévrain et al., 2016, Breyner et al., 2017). 
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